BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-6. [PMID: 21997553 DOI: 10.1136/gutjnl-2011-300730] [Cited by in Crossref: 410] [Cited by in F6Publishing: 434] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Zyla RE, Kalimuthu SN. Barrett’s Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective. Thoracic Surgery Clinics 2022;32:413-424. [DOI: 10.1016/j.thorsurg.2022.06.005] [Reference Citation Analysis]
2 Jajosky A, Fels Elliott DR. Esophageal Cancer Genetics and Clinical Translation. Thoracic Surgery Clinics 2022;32:425-435. [DOI: 10.1016/j.thorsurg.2022.06.002] [Reference Citation Analysis]
3 Uno K, Koike T, Hatta W, Saito M, Tanabe M, Masamune A. Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia. Diagnostics (Basel) 2022;12:2437. [PMID: 36292126 DOI: 10.3390/diagnostics12102437] [Reference Citation Analysis]
4 Sarem M, Martínez Cerezo FJ, Salvia Favieres ML, Corti R. Low-grade dysplasia in Barrett's esophagus: A problematic diagnosis. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.10.002] [Reference Citation Analysis]
5 Berman AG, Tan WK, O'donovan M, Markowetz F, Fitzgerald RC. Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning. eBioMedicine 2022;82:104160. [DOI: 10.1016/j.ebiom.2022.104160] [Reference Citation Analysis]
6 Ma SZ, Chen HX, Liang ZD, Qi XS. Risk factors for Barrett's esophagus: Recent advances. Shijie Huaren Xiaohua Zazhi 2022; 30(14): 605-613 [DOI: 10.11569/wcjd.v30.i14.605] [Reference Citation Analysis]
7 Martínez-domínguez SJ, Lanas Á, Domper-arnal MJ. Barrett’s esophagus, towards improved clinical practice. Medicina Clínica (English Edition) 2022;159:92-100. [DOI: 10.1016/j.medcle.2022.07.003] [Reference Citation Analysis]
8 Pinto R, Hauge T, Jeanmougin M, Pharo HD, Kresse SH, Honne H, Winge SB, Five MB, Kumar T, Mala T, Hauge T, Johnson E, Lind GE. Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus. Clin Epigenetics 2022;14:77. [PMID: 35701814 DOI: 10.1186/s13148-022-01287-7] [Reference Citation Analysis]
9 Watson TJ. What If Endoscopic Eradication Therapy for Esophageal Neoplasia Is Not Good Enough? Foregut 2022;2:116-122. [DOI: 10.1177/26345161221116367] [Reference Citation Analysis]
10 Zhao X, Gabriëls RY, Hooghiemstra WTR, Koller M, Meersma GJ, Buist-Homan M, Visser L, Robinson DJ, Tenditnaya A, Gorpas D, Ntziachristos V, Karrenbeld A, Kats-Ugurlu G, Fehrmann RSN, Nagengast WB. Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett's Esophagus. Cancers (Basel) 2022;14:2462. [PMID: 35626066 DOI: 10.3390/cancers14102462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Johari Y, Budiman K, Catchlove W, Laurie C, Hebbard G, Norden S, Brown WA, Burton P. Tubularized and Effaced Gastric Cardia Mimicking Barrett Esophagus following Sleeve Gastrectomy: Protocolized Endoscopic and Histological Assessment with High-Resolution Manometry Analysis. Ann Surg 2022. [PMID: 35703462 DOI: 10.1097/SLA.0000000000005493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Overwater A, Rueb K, Elias SG, de Bree R, Weusten BLAM. Esophageal Second Primary Tumors in Patients With Head and Neck Squamous Cell Carcinoma: Incidence, Risk Factors, and Overall Survival. Am J Gastroenterol 2022;117:794-7. [PMID: 35213400 DOI: 10.14309/ajg.0000000000001711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Martínez-domínguez SJ, Lanas Á, Domper-arnal MJ. Esófago de Barrett, hacia la mejora de la práctica clínica. Medicina Clínica 2022. [DOI: 10.1016/j.medcli.2022.02.012] [Reference Citation Analysis]
14 Borgmann M, Quante M. Impact of the Tumor Microenvironment for Esophageal Tumor Development—An Opportunity for Prevention? Cancers 2022;14:2246. [DOI: 10.3390/cancers14092246] [Reference Citation Analysis]
15 Puthenpura MM, Sanaka KO, Qin Y, Thota PN. Management of nondysplastic Barrett’s esophagus: When to survey? When to ablate? Therapeutic Advances in Chronic Disease 2022;13:204062232210867. [DOI: 10.1177/20406223221086760] [Reference Citation Analysis]
16 White JR, Ragunath K, Whitton A, Marsh E, Kaye P, Knight G. Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology. BMJ Open Gastroenterol 2022;9:e000840. [PMID: 35379652 DOI: 10.1136/bmjgast-2021-000840] [Reference Citation Analysis]
17 Chan MW, Pouw RE. Risk-stratification models for Barrett’s esophagus: Will we get to the perfect classifier? Gastrointestinal Endoscopy 2022. [DOI: 10.1016/j.gie.2022.02.028] [Reference Citation Analysis]
18 Motomura D, Bechara R. Single operator experience of endoscopic submucosal dissection for Barrett's neoplasia in a North American academic center. DEN Open 2022;2. [DOI: 10.1002/deo2.81] [Reference Citation Analysis]
19 Evans JA, Carlotti E, Lin ML, Hackett RJ, Haughey MJ, Passman AM, Dunn L, Elia G, Porter RJ, McLean MH, Hughes F, ChinAleong J, Woodland P, Preston SL, Griffin SM, Lovat L, Rodriguez-Justo M, Huang W, Wright NA, Jansen M, McDonald SAC. Clonal Transitions and Phenotypic Evolution in Barrett's Esophagus. Gastroenterology 2022;162:1197-1209.e13. [PMID: 34973296 DOI: 10.1053/j.gastro.2021.12.271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Koike T, Saito M, Ohara Y, Hatta W, Masamune A. Current status of surveillance for Barrett's esophagus in Japan and the West. DEN Open 2022;2. [DOI: 10.1002/deo2.94] [Reference Citation Analysis]
21 Katz-Summercorn AC, Jammula S, Frangou A, Peneva I, O'Donovan M, Tripathi M, Malhotra S, di Pietro M, Abbas S, Devonshire G, Januszewicz W, Blasko A, Nowicki-Osuch K, MacRae S, Northrop A, Redmond AM, Wedge DC, Fitzgerald RC. Multi-omic cross-sectional cohort study of pre-malignant Barrett's esophagus reveals early structural variation and retrotransposon activity. Nat Commun 2022;13:1407. [PMID: 35301290 DOI: 10.1038/s41467-022-28237-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Choi KKH, Sanagapalli S. Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies. World J Gastrointest Oncol 2022; 14(3): 568-586 [PMID: 35321279 DOI: 10.4251/wjgo.v14.i3.568] [Reference Citation Analysis]
23 Choi WT, Lauwers GY, Montgomery EA. Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia. Mod Pathol 2022. [PMID: 35260826 DOI: 10.1038/s41379-022-01056-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. [DOI: 10.1007/s00535-022-01861-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
25 Kolb JM, Wani S. Endoscopic Management of Barrett's Esophagus. Dig Dis Sci 2022. [PMID: 35226224 DOI: 10.1007/s10620-022-07395-x] [Reference Citation Analysis]
26 Masqué-soler N, Gehrung M, Kosmidou C, Li X, Diwan I, Rafferty C, Atabakhsh E, Markowetz F, Fitzgerald RC. Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples. eBioMedicine 2022;76:103814. [DOI: 10.1016/j.ebiom.2022.103814] [Reference Citation Analysis]
27 Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, Nowden L, Lash R, Bass AJ, Stachler MD. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia. Gastroenterology 2022;162:468-81. [PMID: 34757142 DOI: 10.1053/j.gastro.2021.10.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
28 Konda VJ, Ellison A, Codipilly DC, Han J, Samarasena J, Iyer PG. Quality in Barrett's Esophagus: Diagnosis and Management. Techniques and Innovations in Gastrointestinal Endoscopy 2022. [DOI: 10.1016/j.tige.2022.01.009] [Reference Citation Analysis]
29 Ekheden I, Ludvigsson JF, Yin L, Elbe P, Ye W. Esophageal abnormalities and the risk for gastroesophageal cancers-a histopathology-register-based study in Sweden. Eur J Epidemiol 2022. [PMID: 34978667 DOI: 10.1007/s10654-021-00833-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Paulose R, Viswanath N, Gopalakrishna R. Nonneoplastic Pathologies of the Esophagus. Surgical Pathology of the Gastrointestinal System 2022. [DOI: 10.1007/978-981-16-6395-6_7] [Reference Citation Analysis]
31 Nieuwenhuis EA, Bergman JJGHM, Pouw RE. Radiofrequency Ablation of Barrett’s Epithelium. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2022. [DOI: 10.1007/978-3-030-56993-8_6] [Reference Citation Analysis]
32 Leclercq P, Bisschops R. Cryotherapy and Argon Ablation of Barrett’s Epithelium. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2022. [DOI: 10.1007/978-3-030-56993-8_7] [Reference Citation Analysis]
33 Heimbucher J, Freys SM. Zwerchfellhernien und gastroösophageale Refluxkrankheit. Allgemein- und Viszeralchirurgie II 2022. [DOI: 10.1016/b978-3-437-24812-2.00006-8] [Reference Citation Analysis]
34 Codipilly DC, Iyer PG. What's next for wide-area transepithelial sampling in Barrett's esophagus management? Gastrointest Endosc 2021:S0016-5107(21)01832-0. [PMID: 34916062 DOI: 10.1016/j.gie.2021.11.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Maslyonkina KS, Konyukova AK, Alexeeva DY, Sinelnikov MY, Mikhaleva LM. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. Cancer Med 2021. [PMID: 34870375 DOI: 10.1002/cam4.4447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Szymański M, Marek I, Wilczyński M, Janczy A, Bigda J, Kaska Ł, Proczko-stepaniak M. Evaluation of esophageal pathology in a group of patients 2 years after one-anastomosis gastric bypass (OAGB) — Cohort study. Obesity Research & Clinical Practice 2021. [DOI: 10.1016/j.orcp.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Panda A, Bhanot G, Ganesan S, Bajpai M. Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:5971. [PMID: 34885081 DOI: 10.3390/cancers13235971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Yao H, Wang L, Li H, Xu S, Bai Z, Wu Y, Chen H, Goyal H, Qi X. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2021;:1-10. [PMID: 34806503 DOI: 10.1080/17512433.2022.2008909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Ventre S, Shahid H. Endoscopic therapies for Barrett's esophagus. Transl Gastroenterol Hepatol 2021;6:62. [PMID: 34805584 DOI: 10.21037/tgh.2020.02.04] [Reference Citation Analysis]
40 van der Ende-van Loon MCM, Stoker A, Nieuwkerk PT, Curvers WL, Schoon EJ. How are we measuring health-related quality of life in patients with a Barrett Esophagus? A systematic review on patient-reported outcome measurements. Qual Life Res 2021. [PMID: 34748137 DOI: 10.1007/s11136-021-03009-7] [Reference Citation Analysis]
41 Chang K, Jackson CS, Vega KJ. Barrett's Esophagus: Diagnosis, Management, and Key Updates. Gastroenterol Clin North Am 2021;50:751-68. [PMID: 34717869 DOI: 10.1016/j.gtc.2021.08.009] [Reference Citation Analysis]
42 Salimian KJ, Birkness-Gartman J, Waters KM. The path(ology) from reflux oesophagitis to Barrett oesophagus to oesophageal adenocarcinoma. Pathology 2021:S0031-3025(21)00482-7. [PMID: 34711413 DOI: 10.1016/j.pathol.2021.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Panda A, Shin MR, Cheng C, Bajpai M. Barrett's Epithelium to Esophageal Adenocarcinoma: Is There a "Point of No Return"? Front Genet 2021;12:706706. [PMID: 34603373 DOI: 10.3389/fgene.2021.706706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Keogan A, Nguyen TNQ, Phelan JJ, O'farrell N, Lynam‐lennon N, Doyle B, O'toole D, Reynolds JV, O'sullivan J, Meade AD. Chemical imaging and machine learning for sub‐classification of oesophageal tissue histology. Transl Biophotonics 2021;3. [DOI: 10.1002/tbio.202100004] [Reference Citation Analysis]
45 Shaheen NJ, Smith MS, Odze RD. Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis. Gastrointest Endosc 2021:S0016-5107(21)01645-X. [PMID: 34537193 DOI: 10.1016/j.gie.2021.09.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
46 Fukuda S, Watanabe K, Yoshida T, Takahashi S, Fujimori S, Horikawa Y, Komatsu T, Shirane K, Shimodaira Y, Matsuhashi T, Iijima K. Low risk of esophageal adenocarcinoma among patients with ultrashort-segment Barrett's esophagus in Japan. Dig Endosc 2021. [PMID: 34437742 DOI: 10.1111/den.14118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
47 Grillo F, Mastracci L, Saragoni L, Vanoli A, Limarzi F, Gullo I, Ferro J, Paudice M, Parente P, Fassan M. Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. Pathologica 2020;112:138-52. [PMID: 33179618 DOI: 10.32074/1591-951X-164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Na R, Miura K, O'Brien S, Eslick GD, Kendall BJ, Hourigan LF, Bourke M, Cox MR, Farrokhzadi L, Levert-Mignon AJ, Barbour AP, Clemons NJ, Duong CP, Lord RV, Phillips WA, Watson DI, Whiteman DC. Clinical pathways and outcomes of patients with Barrett's esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008-2016. Dis Esophagus 2021;34:doaa119. [PMID: 33306781 DOI: 10.1093/dote/doaa119] [Reference Citation Analysis]
49 Suresh Kumar VC, Harne P, Patthipati VS, Subedi A, Masood U, Sharma A, Goyal F, Aggarwal N, Sapkota B. Wide-area transepithelial sampling in adjunct to forceps biopsy increases the absolute detection rates of Barrett's oesophagus and oesophageal dysplasia: a meta-analysis and systematic review. BMJ Open Gastroenterol 2020;7:e000494. [PMID: 32928869 DOI: 10.1136/bmjgast-2020-000494] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
50 Tan WK, Sharma AN, Chak A, Fitzgerald RC. Progress in Screening for Barrett's Esophagus: Beyond Standard Upper Endoscopy. Gastrointest Endosc Clin N Am 2021;31:43-58. [PMID: 33213799 DOI: 10.1016/j.giec.2020.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Leclercq P, Bisschops R. Optimizing Outcomes with Radiofrequency Ablation of Barrett's Esophagus: Candidates, Efficacy and Durability. Gastrointest Endosc Clin N Am 2021;31:131-54. [PMID: 33213792 DOI: 10.1016/j.giec.2020.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Liu X, Goldblum JR. Role of Histology and Cytology in Esophageal Diseases. The Esophagus 2021. [DOI: 10.1002/9781119599692.ch12] [Reference Citation Analysis]
53 Klaver E, Bureo Gonzalez A, Mostafavi N, Mallant-Hent R, Duits LC, Baak B, Böhmer CJM, van Oijen AHAM, Naber T, Scholten P, Meijer SL, Bergman JJGHM, Pouw RE; ReBus Study Group. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression. United European Gastroenterol J 2021. [PMID: 34228885 DOI: 10.1002/ueg2.12114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Xiao YL, Zhou LY, Hou XH, Li YQ, Zou DW, Chen MH; Chinese Society of Gastroenterology. Chinese expert consensus on gastroesophageal reflux disease in 2020. J Dig Dis 2021;22:376-89. [PMID: 34105263 DOI: 10.1111/1751-2980.13028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
55 Graham DY, Tan MC. No Barrett's-No Cancer: A Proposed New Paradigm for Prevention of Esophageal Adenocarcinoma. J Clin Gastroenterol 2020;54:136-43. [PMID: 31851107 DOI: 10.1097/MCG.0000000000001298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Clauditz TS, Lauwers GY, Wallace MB, Mattia AR. Epithelial Metaplastic, Polypoid, and Neoplastic Conditions of the Esophagus. Gastrointestinal Pathology 2021. [DOI: 10.1002/9781119073048.ch3] [Reference Citation Analysis]
57 Hanschmidt F, Treml J, Kreuser N, Gockel I, Kersting A. Anxiety and depression in patients with Barrett's esophagus: estimates of disorder rates and associations with symptom load and treatment-seeking. Eur J Gastroenterol Hepatol 2021;33:825-31. [PMID: 33136727 DOI: 10.1097/MEG.0000000000001960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Platt KD, Schulman AR. Screening for Barrett's esophagus after sleeve gastrectomy. Gastrointest Endosc 2021;93:353-5. [PMID: 33478660 DOI: 10.1016/j.gie.2020.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Groulx S, Limburg H, Doull M, Klarenbach S, Singh H, Wilson BJ, Thombs B; Canadian Task Force on Preventive Health Care. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease. CMAJ 2020;192:E768-77. [PMID: 32631908 DOI: 10.1503/cmaj.190814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Sogabe M, Okahisa T, Kurihara T, Kagawa M, Kagemoto K, Kida Y, Tomonari T, Taniguchi T, Okamoto K, Miyamoto H, Sato Y, Nakasono M, Takayama T. Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study. Diabetes Metab Syndr Obes 2021;14:1589-600. [PMID: 33883913 DOI: 10.2147/DMSO.S298326] [Reference Citation Analysis]
61 Evans JA, Carlotti E, Lin M, Hackett RJ, Passman A, Dunn L, Elia G, Porter RJ, Mcclean MH, Hughes F, Chinaleong J, Woodland P, Preston SL, Griffin SM, Lovat L, Rodriguez-justo M, Wright NA, Jansen M, Mcdonald SA. Clonal transitions and phenotypic evolution in Barrett esophagus.. [DOI: 10.1101/2021.03.31.21252894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Konda VJ, Ellison A. The Utility of Biomarkers for Risk Stratification in Barrett’s Esophagus. Foregut 2021;1:41-47. [DOI: 10.1177/2634516121995027] [Reference Citation Analysis]
63 Cotton CC, Shaheen NJ. Commentary on: The Utility of Biomarkers for Risk Stratification in Barrett’s Esophagus. Foregut 2021;1:48-49. [DOI: 10.1177/2634516121997232] [Reference Citation Analysis]
64 Dhaliwal L, Iyer PG. State of the Art: Management of Barrett’s Esophagus Related Dysplasia and Neoplasia—Which Patient and What Therapy? Foregut 2021;1:68-77. [DOI: 10.1177/2634516121993260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Scarpignato C, Wang DH. Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine. Foregut 2021;1:50-62. [DOI: 10.1177/2634516121993676] [Reference Citation Analysis]
66 Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol 2021;18:432-43. [PMID: 33603224 DOI: 10.1038/s41575-021-00419-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 38.0] [Reference Citation Analysis]
67 Diehl DL, Khara HS, Akhtar N, Critchley-Thorne RJ. TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus. Endosc Int Open 2021;9:E348-55. [PMID: 33655033 DOI: 10.1055/a-1326-1533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
68 Phillips R, Januszewicz W, Pilonis ND, O'Donovan M, Sawas T, Katzka DA, Fitzgerald RC, di Pietro M. The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study. Gastrointest Endosc 2021;94:263-270.e2. [PMID: 33548281 DOI: 10.1016/j.gie.2021.01.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
69 Sato H, Terai S, Shimamura Y, Tanaka S, Shiwaku H, Minami H, Sato C, Ogawa R, Yokomichi H, Inoue H. Achalasia and esophageal cancer: a large database analysis in Japan. J Gastroenterol 2021;56:360-70. [PMID: 33538893 DOI: 10.1007/s00535-021-01763-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
70 Post AL, de Groof AJ, Zhang XU, Swager AF, Fockens KN, Pouw RE, Weusten BLAM, Faber DJ, de Bruin DM, Bergman JJGHM, van Leeuwen TG, Sterenborg HJCM, Curvers WL. Toward improved endoscopic surveillance with multidiameter single fiber reflectance spectroscopy in patients with Barrett's esophagus. J Biophotonics 2021;14:e202000351. [PMID: 33410602 DOI: 10.1002/jbio.202000351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
71 Reeh M, Izbicki JR. Chirurgische Therapieoptionen bei Barrett-Metaplasie und -Dysplasie des Ösophagus. Benigne Ösophaguserkrankungen 2021. [DOI: 10.1007/978-3-662-60455-7_26] [Reference Citation Analysis]
72 Rath T, Neurath MF, Atreya R. Molecular Imaging and its Applications in Selected GI Diseases. Techniques and Innovations in Gastrointestinal Endoscopy 2021;23:87-98. [DOI: 10.1016/j.tige.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Shrimal P, Banerjee R, Chiu PWY. Endoscopic Diagnosis of Superficial Esophageal Neoplasia. Endoscopy in Early Gastrointestinal Cancers, Volume 1 2021. [DOI: 10.1007/978-981-10-6769-3_3] [Reference Citation Analysis]
74 Rath T, Neurath MF, Atreya R. Molecular Endoscopic Imaging in Cancer. Molecular Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00010-7] [Reference Citation Analysis]
75 Hollenbach M, Hoffmeister A. Endoskopisches Management und interventionelle Therapie der Barrett-Metaplasie und der intraepithelialen Neoplasie des Ösophagus. Benigne Ösophaguserkrankungen 2021. [DOI: 10.1007/978-3-662-60455-7_25] [Reference Citation Analysis]
76 Wani S, Williams JL, Falk GW, Komanduri S, Muthusamy VR, Shaheen NJ. An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. Am J Gastroenterol 2020;115:1869-78. [PMID: 33156106 DOI: 10.14309/ajg.0000000000000960] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
77 Norita K, Koike T, Saito M, Shinkai H, Ami R, Abe Y, Dairaku N, Inomata Y, Kayaba S, Ishiyama F, Oikawa T, Ohyauchi M, Ito H, Asonuma S, Hoshi T, Kato K, Ohara S, Shimodaira Y, Watanabe K, Shimosegawa T, Masamune A, Iijima K. Long-term endoscopic surveillance for Barrett's esophagus in Japan: Multicenter prospective cohort study. Dig Endosc 2021;33:1085-92. [PMID: 33277694 DOI: 10.1111/den.13910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Musella M, Vitiello A, Berardi G, Velotti N, Pesce M, Sarnelli G. Evaluation of reflux following sleeve gastrectomy and one anastomosis gastric bypass: 1-year results from a randomized open-label controlled trial. Surg Endosc 2020. [PMID: 33269429 DOI: 10.1007/s00464-020-08182-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
79 Kroupa R, Katinova I, Pavlik T, Kunovsky L, Prochazka V, Borilova Linhartova P, Packova B, Kala Z, Dolina J. Incidence trends of esophageal cancer in the Czech Republic by histological subtype and stage and prescription rate of acid suppressing drugs. Cancer Epidemiol 2020;69:101853. [PMID: 33161372 DOI: 10.1016/j.canep.2020.101853] [Reference Citation Analysis]
80 Zhang J, Wu H, Wang R. Effect of nonsteroidal anti-inflammatory drugs on Barrett's esophagus risk: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101552. [PMID: 33268293 DOI: 10.1016/j.clinre.2020.09.013] [Reference Citation Analysis]
81 Triggs JR, Falk GW. Best Practices in Surveillance for Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:59-75. [PMID: 33213800 DOI: 10.1016/j.giec.2020.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Redston M, Noffsinger A, Kim A, Akarca FG, Stapleton D, Nowden L, Lash R, Bass AJ, Stachler MD. Abnormal TP53 predicts risk of progression in patients with Barrett’s esophagus regardless of a diagnosis of dysplasia.. [DOI: 10.1101/2020.10.18.20213561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Peleg N, Schmilovitz-Weiss H, Shamah S, Schwartz A, Dotan I, Sapoznikov B. Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus. Endoscopy 2021;53:774-81. [PMID: 33075822 DOI: 10.1055/a-1292-8747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Amano Y, Ishimura N, Ishihara S. Is Malignant Potential of Barrett’s Esophagus Predictable by Endoscopy Findings? Life 2020;10:244. [DOI: 10.3390/life10100244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Bernal Vaca ML, Garcia Arévalo HF, De Molano BM. Caracterización demográfica de la población con esófago de Barrett en dos instituciones médicas de Bogotá, Colombia. Rev Colomb Gastroenterol 2020;35:311-318. [DOI: 10.22516/25007440.488] [Reference Citation Analysis]
86 Cotton CC, Shaheen NJ. Overutilization of Endoscopic Surveillance in Barrett's Esophagus: The Perils of Too Much of a Good Thing. Am J Gastroenterol 2020;115:1019-21. [PMID: 32618650 DOI: 10.14309/ajg.0000000000000650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Davison JM, Goldblum J, Grewal US, McGrath K, Fasanella K, Deitrick C, DeWard AD, Bossart EA, Hayward SL, Zhang Y, Critchley-Thorne RJ, Thota PN. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus. Am J Gastroenterol 2020;115:843-52. [PMID: 32079863 DOI: 10.14309/ajg.0000000000000556] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
88 Barrie J, Yanni F, Sherif M, Dube AK, Tamhankar AP. Length of Barrett's esophagus in the presence of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Surg Endosc 2021;35:4756-62. [PMID: 32880012 DOI: 10.1007/s00464-020-07950-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Gibbens Y, Iyer PG. What Is the Optimal Surveillance Strategy for Non-dysplastic Barrett’s Esophagus? Curr Treat Options Gastro 2020;18:369-383. [DOI: 10.1007/s11938-020-00297-9] [Reference Citation Analysis]
90 Scarpignato C, Sloan JA, Wang DH, Hunt RH. Gastrointestinal pharmacology: practical tips for the esophagologist. Ann N Y Acad Sci 2020;1481:90-107. [PMID: 32822080 DOI: 10.1111/nyas.14447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
91 Badgery H, Read M, Winter NN, Taylor ACF, Hii MW. The role of esophagectomy in the management of Barrett's esophagus with high-grade dysplasia. Ann N Y Acad Sci 2020;1481:72-89. [PMID: 32812261 DOI: 10.1111/nyas.14439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Di J, Sharma N, Pérez LKM, Zhang J, Ho KY. Surveillance strategy of Barrett's esophagus in the Asian region with particular reference to its locoregional epidemiology. JGH Open 2020;4:565-8. [PMID: 32782939 DOI: 10.1002/jgh3.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 di Pietro M, Bertani H, OʼDonovan M, Santos P, Alastal H, Phillips R, Ortiz-Fernández-Sordo J, Iacucci M, Modolell I, Reggiani Bonetti L, Ragunath K, Wernisch L. Development and Validation of Confocal Endomicroscopy Diagnostic Criteria for Low-Grade Dysplasia in Barrett's Esophagus. Clin Transl Gastroenterol 2019;10:e00014. [PMID: 30985335 DOI: 10.14309/ctg.0000000000000014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
94 Kunovský L, Kala Z, Kroupa R, Grolich T, Dolina J, Dastych M, Vaculová J, Vlažný J, Moravčík P, Izakovičová Hollá L, Bořilová Linhartová P, Jabandžiev P, Procházka V. Confocal laser endomicroscopy in the diagnostics of esophageal diseases: a pilot study. Vnitr Lek 2020;66:e26-e32. [DOI: 10.36290/vnl.2020.094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Januszewicz W, Subhash VV, Waldock W, Fernando DI, Bartalucci G, Chettouh H, Miremadi A, O'Donovan M, Fitzgerald RC, di Pietro M. The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus. EBioMedicine 2020;58:102877. [PMID: 32707444 DOI: 10.1016/j.ebiom.2020.102877] [Reference Citation Analysis]
96 Rouphael C, Anil Kumar M, Sanaka MR, Thota PN. Indications, contraindications and limitations of endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma. Therap Adv Gastroenterol 2020;13:1756284820924209. [PMID: 32523628 DOI: 10.1177/1756284820924209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
97 Maitra I, Date RS, Martin FL. Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.Clin J Gastroenterol. 2020;13:635-649. [PMID: 32495144 DOI: 10.1007/s12328-020-01135-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
98 Hadjinicolaou AV, van Munster SN, Achilleos A, Santiago Garcia J, Killcoyne S, Ragunath K, Bergman JJGHM, Fitzgerald RC, di Pietro M. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study. EBioMedicine 2020;56:102765. [PMID: 32460165 DOI: 10.1016/j.ebiom.2020.102765] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
99 van der Wel MJ, Coleman HG, Bergman JJGHM, Jansen M, Meijer SL; BOLERO working group. Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using digital pathology. Gut 2020;69:811-22. [PMID: 31852770 DOI: 10.1136/gutjnl-2019-318985] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
100 Britton J, Taxiarchi P, Martin G, Willert R, Horne M, Hamdy S, McLaughlin J, Ang Y. Comparative quantitative survey of patient experience in Barrett's oesophagus and other gastrointestinal disorders. BMJ Open Gastroenterol 2020;7:e000357. [PMID: 32337055 DOI: 10.1136/bmjgast-2019-000357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Hoefnagel SJM, Mostafavi N, Timmer MR, Lau CT, Meijer SL, Wang KK, Krishnadath KK. A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts. PLoS One 2020;15:e0231419. [PMID: 32282835 DOI: 10.1371/journal.pone.0231419] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
102 Ron LM, Domínguez-muñoz J. Esófago de Barrett. Neoplasias esofágicas. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:392-400. [DOI: 10.1016/j.med.2020.05.004] [Reference Citation Analysis]
103 Inadomi JM. What's App with GERD? Gastroenterology 2020;158:1211-2. [PMID: 32004529 DOI: 10.1053/j.gastro.2020.01.033] [Reference Citation Analysis]
104 O’byrne LM, Witherspoon J, Verhage RJJ, O’brien M, Muldoon C, Ryan C, Buckley M, Murphy T, Reynolds R, Patchett S, Kay E, Azam H, Robb W, Arumugasamy M, Mathuna PM, Leyden J, Gargan S, Doherty G, Sheahan K, Collins C, Nath A, O’sullivan J, Donohoe CL, Ravi N, O’toole D, Reynolds JV. Barrett’s Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett’s esophagus: report of the RIBBON network. Diseases of the Esophagus 2020;33:doaa009. [DOI: 10.1093/dote/doaa009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
105 Fitzgerald RC, di Pietro M. Diseases of the oesophagus. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0294] [Reference Citation Analysis]
106 ASGE Standards of Practice Committee, Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, Agrawal D, Buxbaum JL, Fishman DS, Gurudu SR, Jue TL, Kripalani S, Lee JK, Khashab MA, Naveed M, Thosani NC, Yang J, DeWitt J, Wani S; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90:335-359.e2. [PMID: 31439127 DOI: 10.1016/j.gie.2019.05.012] [Cited by in Crossref: 144] [Cited by in F6Publishing: 108] [Article Influence: 72.0] [Reference Citation Analysis]
107 Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, Falck-Ytter Y, Mustafa RA. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020;158:693-702. [PMID: 31816298 DOI: 10.1053/j.gastro.2019.12.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 101] [Article Influence: 50.5] [Reference Citation Analysis]
108 Callahan ZM, Shi Z, Su B, Xu J, Ujiki M. Genetic variants in Barrett's esophagus and esophageal adenocarcinoma: a literature review. Dis Esophagus 2019;32:doz017. [PMID: 30888413 DOI: 10.1093/dote/doz017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Bevers T, El-serag H, Hanash S, Thrift AP, Tsai K, Maresso KC, Hawk E. Screening and Early Detection. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00023-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Ku GY, Ilson DH. Cancer of the Esophagus. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00071-2] [Reference Citation Analysis]
111 Serha TV, Kuryk OH, Yakovenko VO, Tkachenko RP. RISK OF ADENOCARCINOMA IN BARRETT'S ESOPHAGUS. WOMAB 2020;16:120. [DOI: 10.26724/2079-8334-2020-1-71-120-124] [Reference Citation Analysis]
112 Labenz J, Labenz C. Vorsorgegastroskopie – lohnt sich das wirklich? Prävention gastroenterologischer Tumorerkrankungen 2020. [DOI: 10.1007/978-3-662-58879-6_7] [Reference Citation Analysis]
113 Leclercq P, Bisschops R. Cryotherapy and Argon Ablation of Barrett’s Epithelium. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2020. [DOI: 10.1007/978-3-030-29964-4_7-1] [Reference Citation Analysis]
114 Suzuki K, Akazawa N, Fujisaki J. Esophageal Cancer: Barrett’s Esophageal Adenocarcinoma (BEA). Endoscopic Treatment Strategy for Upper GI Tract Neoplasms 2020. [DOI: 10.1007/978-981-32-9737-1_1] [Reference Citation Analysis]
115 Kuvaev R, Nikonov E, Vidyayeva N, Kashin S, Zharova M. Analysis of the ASGE guideline on screening and surveillance of Barrett’s esophagus. Dok gastroenterol 2020;9:30. [DOI: 10.17116/dokgastro2020902130] [Reference Citation Analysis]
116 Holzapfel K, Kaulfuß S, Neu B, Rexrodt P, Rieger L, Vehling-kaiser U, Venkataramani V. Was ist Krebs? Onkologische Erkrankungen in der Hausarztpraxis 2020. [DOI: 10.1016/b978-3-437-21271-0.00002-5] [Reference Citation Analysis]
117 Krishnamoorthi R, Mohan BP, Jayaraj M, Wang KK, Katzka DA, Ross A, Adler DG, Iyer PG. Risk of progression in Barrett’s esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2020;91:3-10.e3. [DOI: 10.1016/j.gie.2019.07.037] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
118 Nieuwenhuis EA, Bergman JJGHM, Pouw RE. Radiofrequency Ablation of Barrett’s Epithelium. Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy 2020. [DOI: 10.1007/978-3-030-29964-4_6-1] [Reference Citation Analysis]
119 Kaibysheva V, Kashin S, Karasev A, Merkulova A, Krainova E, Fedorov E, Shapovalyants S. Update on Barrett’s esophagus diagnosis and treatment. Dok gastroenterol 2020;9:33. [DOI: 10.17116/dokgastro2020904133] [Reference Citation Analysis]
120 Nachiappan A, Ragunath K, Card T, Kaye P. Diagnosing dysplasia in Barrett's oesophagus still requires Seattle protocol biopsy in the era of modern video endoscopy: results from a tertiary centre Barrett's dysplasia database. Scand J Gastroenterol 2020;55:9-13. [PMID: 31880176 DOI: 10.1080/00365521.2019.1706762] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 Porter RJ, Murray GI, Brice DP, Petty RD, McLean MH. Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype. Br J Cancer 2020;122:545-54. [PMID: 31831860 DOI: 10.1038/s41416-019-0685-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
122 Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi M, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E. Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer. Updates Surg 2019;71:599-624. [DOI: 10.1007/s13304-019-00696-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Ingham J, Pilling MJ, Martin DS, Smith CI, Ellis BG, Whitley CA, Siggel-king MR, Harrison P, Craig T, Varro A, Pritchard DM, Varga A, Gardner P, Weightman P, Barrett S. A novel FTIR analysis method for rapid high-confidence discrimination of esophageal cancer. Infrared Physics & Technology 2019;102:103007. [DOI: 10.1016/j.infrared.2019.103007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
124 Hao J, Critchley-Thorne R, Diehl DL, Snyder SR. A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett's Esophagus. Clinicoecon Outcomes Res 2019;11:623-35. [PMID: 31749626 DOI: 10.2147/CEOR.S221741] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
125 Iyer PG, Kaul V. Barrett Esophagus. Mayo Clinic Proceedings 2019;94:1888-901. [DOI: 10.1016/j.mayocp.2019.01.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
126 Karamchandani DM, Zhang Q, Liao XY, Xu JH, Liu XL. Inflammatory bowel disease- and Barrett's esophagus-associated neoplasia: the old, the new, and the persistent struggles. Gastroenterol Rep (Oxf) 2019;7:379-95. [PMID: 31857901 DOI: 10.1093/gastro/goz032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Sami SS, Ravindran A, Kahn A, Snyder D, Santiago J, Ortiz-Fernandez-Sordo J, Tan WK, Dierkhising RA, Crook JE, Heckman MG, Johnson ML, Lansing R, Ragunath K, di Pietro M, Wolfsen H, Ramirez F, Fleischer D, Wang KK, Leggett CL, Katzka DA, Iyer PG. Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study. Gut 2019;68:1379-85. [PMID: 30635408 DOI: 10.1136/gutjnl-2018-317513] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 17.3] [Reference Citation Analysis]
128 Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F. Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. J Clin Gastroenterol 2018;52:401-6. [PMID: 28422774 DOI: 10.1097/MCG.0000000000000790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
129 Dalal KS, Coffing J, Imperiale TF. Adherence to Surveillance Guidelines in Nondysplastic Barrett's Esophagus. J Clin Gastroenterol. 2018;52:217-222. [PMID: 27984402 DOI: 10.1097/mcg.0000000000000777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
130 Hiremath G, Locke A, Sivakumar A, Thomas G, Mahadevan-Jansen A. Clinical translational application of Raman spectroscopy to advance Benchside biochemical characterization to bedside diagnosis of esophageal diseases. J Gastroenterol Hepatol 2019;34:1911-21. [PMID: 31124184 DOI: 10.1111/jgh.14738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
131 Amano Y, Nakahara R, Yuki T, Murakami D, Ujihara T, Tomoyuki I, Sagami R, Suehiro S, Katsuyama Y, Hayasaka K, Harada H, Tada Y, Miyaoka Y, Fujishiro H. Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. J Gastroenterol 2019;54:984-93. [PMID: 31240437 DOI: 10.1007/s00535-019-01600-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
132 Britton J, Chatten K, Riley T, Keld RR, Hamdy S, McLaughlin J, Ang Y. Dedicated service improves the accuracy of Barrett's oesophagus surveillance: a prospective comparative cohort study. Frontline Gastroenterol 2019;10:128-34. [PMID: 31205652 DOI: 10.1136/flgastro-2018-101019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Garalla HM, Lertkowit N, Tiszlavicz L, Reisz Z, Holmberg C, Beynon R, Simpson D, Varga A, Kumar JD, Dodd S, Pritchard DM, Moore AR, Rosztóczy AI, Wittman T, Simpson A, Dockray GJ, Varro A. Matrix metalloproteinase (MMP)-7 in Barrett's esophagus and esophageal adenocarcinoma: expression, metabolism, and functional significance. Physiol Rep 2018;6:e13683. [PMID: 29845775 DOI: 10.14814/phy2.13683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
134 O'Donovan M, Fitzgerald RC. Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible? Dig Dis Sci 2018;63:2105-14. [PMID: 29995243 DOI: 10.1007/s10620-018-5192-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
135 Odze R. Histology of Barrett's Metaplasia: Do Goblet Cells Matter? Dig Dis Sci 2018;63:2042-51. [PMID: 29998421 DOI: 10.1007/s10620-018-5151-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
136 Sen M, Hahn F, Black TA, DeMarshall M, Porter W, Snowden E, Yee SS, Tong F, Ferguson M, Fleshman EN, Nakagawa H, Falk GW, Ginsberg GG, Kochman ML, Blaesius R, Rustgi AK, Carpenter EL. Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. Oncotarget 2019;10:3592-604. [PMID: 31217895 DOI: 10.18632/oncotarget.26911] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
137 Iwaya Y, Shimamura Y, Mosko JD, Kandel G, Kortan PP, May GR, Marcon NE, Teshima CW. Clinical characteristics may distinguish patients with esophageal adenocarcinoma arising from long- versus short-segment Barrett's esophagus. Dig Liver Dis 2019;51:1470-4. [PMID: 31147211 DOI: 10.1016/j.dld.2019.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Peters Y, Al-kaabi A, Shaheen NJ, Chak A, Blum A, Souza RF, Di Pietro M, Iyer PG, Pech O, Fitzgerald RC, Siersema PD. Barrett oesophagus. Nat Rev Dis Primers 2019;5. [DOI: 10.1038/s41572-019-0086-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 18.7] [Reference Citation Analysis]
139 Lv J, Guo L, Liu JJ, Zhao HP, Zhang J, Wang JH. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma. World J Gastroenterol 2019; 25(18): 2149-2161 [PMID: 31143067 DOI: 10.3748/wjg.v25.i18.2149] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
140 Brücher BL, Lang F, Jamall IS, Bandapalli OR. NF- κ B signaling and crosstalk during carcinogenesis. 4open 2019;2:13. [DOI: 10.1051/fopen/2019010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
141 Sepulveda JL, Komissarova EV, Kongkarnka S, Friedman RA, Davison JM, Levy B, Bryk D, Jobanputra V, Del Portillo A, Falk GW, Sonett JR, Lightdale CJ, Abrams JA, Wang TC, Sepulveda AR. High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. Int J Cancer 2019;145:2754-66. [PMID: 31001805 DOI: 10.1002/ijc.32351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
142 Fukutomi T, Ichikawa H, Hatsugai K, Ohara M, Ottomo S, Sato A, Kohyama A, Kajiwara T, Itakura Y, Takahashi T. Barrett Esophageal Adenocarcinoma with Coexisting Giant Hiatal Hernia, Treated with Simultaneous Hiatal Hernia Repair and Esophagectomy by Thoracoscopic and Laparoscopic Approaches. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2019;52:239-246. [DOI: 10.5833/jjgs.2018.0111] [Reference Citation Analysis]
143 Patel A, Gyawali CP. Screening for Barrett's Esophagus: Balancing Clinical Value and Cost-effectiveness. J Neurogastroenterol Motil 2019;25:181-8. [PMID: 30827080 DOI: 10.5056/jnm18156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
144 Duits LC, Lao-Sirieix P, Wolf WA, O'Donovan M, Galeano-Dalmau N, Meijer SL, Offerhaus GJA, Redman J, Crawte J, Zeki S, Pouw RE, Chak A, Shaheen NJ, Bergman JJGHM, Fitzgerald RC. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. Dis Esophagus. 2019;32. [PMID: 30496496 DOI: 10.1093/dote/doy102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
145 Rogerson C, Britton E, Withey S, Hanley N, Ang YS, Sharrocks AD. Identification of a primitive intestinal transcription factor network shared between esophageal adenocarcinoma and its precancerous precursor state. Genome Res 2019;29:723-36. [PMID: 30962179 DOI: 10.1101/gr.243345.118] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
146 Fitzgerald RC, Corley DA. Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus? Gastroenterology 2019;156:1228-31. [PMID: 30849313 DOI: 10.1053/j.gastro.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Noordzij IC, Curvers WL, Schoon EJ. Endoscopic resection for early esophageal carcinoma. J Thorac Dis 2019;11:S713-22. [PMID: 31080649 DOI: 10.21037/jtd.2019.03.19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
148 Haboubi HN, Lawrence RL, Rees B, Williams L, Manson JM, Al-Mossawi N, Bodger O, Griffiths P, Thornton C, Jenkins GJ. Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma. Sci Rep 2019;9:5168. [PMID: 30914682 DOI: 10.1038/s41598-019-41490-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
149 Wani S, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Over-Utilization of Repeat Upper Endoscopy in Patients with Non-dysplastic Barrett's Esophagus: A Quality Registry Study. Am J Gastroenterol 2019;114:1256-64. [DOI: 10.14309/ajg.0000000000000184] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
150 Fritz T, Schöfl R, Wewalka F, Ziachehabi A. Therapeutic endoscopic strategies in early esophageal cancer and dysplastic Barrett’s epithelium. memo 2019;12:36-41. [DOI: 10.1007/s12254-018-0461-6] [Reference Citation Analysis]
151 Nguyen AD, Spechler SJ, Dunbar KB. Barrett's Esophagus. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch2] [Reference Citation Analysis]
152 Januszewicz W, Fitzgerald RC. Early detection and therapeutics. Mol Oncol. 2019;13:599-613. [PMID: 30677217 DOI: 10.1002/1878-0261.12458] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
153 Newell F, Patel K, Gartside M, Krause L, Brosda S, Aoude LG, Loffler KA, Bonazzi VF, Patch AM, Kazakoff SH, Holmes O, Xu Q, Wood S, Leonard C, Lampe G, Lord RV, Whiteman DC, Pearson JV, Nones K, Waddell N, Barbour AP. Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples. BMC Med Genomics 2019;12:31. [PMID: 30717762 DOI: 10.1186/s12920-019-0476-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
154 Thomas T, Loke Y, Beales ILP. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma. J Gastrointest Cancer 2018;49:442-54. [PMID: 28691139 DOI: 10.1007/s12029-017-9983-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
155 Latos W, Bugaj AM, Sieroń A, Kawczyk-Krupka A. Stratification of the dysplasia and neoplasia risk using autofluorescence endoscopic surveillance of Barrett's esophagus. Photodiagnosis Photodyn Ther 2019;25:285-91. [PMID: 30648638 DOI: 10.1016/j.pdpdt.2019.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
156 Lv J, Guo L, Wang JH, Yan YZ, Zhang J, Wang YY, Yu Y, Huang YF, Zhao HP. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett’s esophagus. World J Gastroenterol 2019; 25(2): 233-244 [PMID: 30670912 DOI: 10.3748/wjg.v25.i2.233] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
157 Shamal' MV, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus, Varabei AI, Maskalik ZG, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus, Minsk Regional Clinical Hospital. BARRETT’S ESOPHAGUS: CONTEMPORARY DIAGNOSTIC AND THERAPEUTIC APPROACHES. Hepatol Gastroenterol 2019;3:103-108. [DOI: 10.25298/2616-5546-2019-3-1-103-108] [Reference Citation Analysis]
158 Watson TJ. Controversies in the Definition of Barrett Esophagus. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00031-5] [Reference Citation Analysis]
159 Waterhouse DJ. Flexible Endoscopy: Early Detection of Dysplasia in Barrett’s Oesophagus. Springer Theses 2019. [DOI: 10.1007/978-3-030-21481-4_2] [Reference Citation Analysis]
160 Antaki F, Judd S, Kanaan Z, Patel SM, Lilley KK. Screening for Gastrointestinal Cancers. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_32] [Reference Citation Analysis]
161 Fisher OM, Lord RV. Epidemiology of Barrett Esophagus and Risk Factors for Progression. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00032-7] [Reference Citation Analysis]
162 Jackson HT, Wright AS. The Role of Photodynamic Therapy and Cryotherapy for the Management of Barrett’s Esophagus. The SAGES Manual of Foregut Surgery 2019. [DOI: 10.1007/978-3-319-96122-4_30] [Reference Citation Analysis]
163 Iovino P, Santonicola A, Trudgill NJ. Pathophysiology of Gastroesophageal Reflux Disease and Natural History of Barrett’s Esophagus. Revisiting Barrett's Esophagus 2019. [DOI: 10.1007/978-3-319-92093-1_4] [Reference Citation Analysis]
164 Sloan J, Katz PO. Gastroesophageal Reflux Disease. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00015-7] [Reference Citation Analysis]
165 Falk GW, Wani S. Barrett's Esophagus. Clinical Gastrointestinal Endoscopy 2019. [DOI: 10.1016/b978-0-323-41509-5.00025-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Rajaram R, Hofstetter WL. Mucosal Ablation Techniques for Barrett's Esophagus and Early Esophageal Cancer. Thorac Surg Clin 2018;28:473-80. [PMID: 30268293 DOI: 10.1016/j.thorsurg.2018.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
167 Kandiah K, Chedgy FJQ, Subramaniam S, Longcroft-Wheaton G, Bassett P, Repici A, Sharma P, Pech O, Bhandari P. International development and validation of a classification system for the identification of Barrett's neoplasia using acetic acid chromoendoscopy: the Portsmouth acetic acid classification (PREDICT). Gut 2018;67:2085-91. [PMID: 28970288 DOI: 10.1136/gutjnl-2017-314512] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
168 Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium. Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology 2018;155:1720-1728.e4. [PMID: 30165050 DOI: 10.1053/j.gastro.2018.08.036] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
169 Lee SW, Lien HC, Peng YC, Lin MX, Ko CW, Chang CS. The incidence of esophageal cancer and dysplasia in a Chinese population with nondysplastic Barrett's esophagus. JGH Open 2018;2:214-6. [PMID: 30483592 DOI: 10.1002/jgh3.12075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
170 Marshall JK. In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not. Ann Intern Med 2018;169:JC54. [DOI: 10.7326/acpjc-2018-169-10-054] [Reference Citation Analysis]
171 Waterhouse DJ, Joseph J, Neves AA, di Pietro M, Brindle KM, Fitzgerald RC, Bohndiek SE. Design and validation of a near-infrared fluorescence endoscope for detection of early esophageal malignancy. J Biomed Opt 2016;21:84001. [PMID: 27490221 DOI: 10.1117/1.JBO.21.8.084001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
172 Davison JM, Shah MB, Deitrick C, Chennat J, Fasanella KE, Mcgrath K. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett’s esophagus risk stratification proficiency in independent pathology practices. Gastrointestinal Endoscopy 2018;88:807-815.e2. [DOI: 10.1016/j.gie.2018.06.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
173 Alkaddour A, McGaw C, Hritani R, Palacio C, Munoz JC, Vega KJ. Protective Propensity of Race or Environmental Features in the Development of Barrett's Esophagus in African Americans - A Single Center Pilot Study. J Natl Med Assoc 2019;111:198-201. [PMID: 30366610 DOI: 10.1016/j.jnma.2018.09.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Sawas T, Manrique GC, Iyer PG, Wang KK, Katzka DA. Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times. Clin Gastroenterol Hepatol 2019;17:1756-62. [PMID: 30267861 DOI: 10.1016/j.cgh.2018.09.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
175 Singh T, Sanaka MR, Thota PN. Endoscopic therapy for Barrett’s esophagus and early esophageal cancer: Where do we go from here? World J Gastrointest Endosc 2018; 10(9): 165-174 [PMID: 30283599 DOI: 10.4253/wjge.v10.i9.165] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
176 Lin EC, Holub J, Lieberman D, Hur C. Low Prevalence of Suspected Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease Without Alarm Symptoms. Clin Gastroenterol Hepatol 2019;17:857-63. [PMID: 30196157 DOI: 10.1016/j.cgh.2018.08.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
177 Singhal S, Kapoor H, Subramanian S, Agrawal DK, Mittal SK. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma. J Gastrointest Cancer 2019;50:867-78. [PMID: 30187205 DOI: 10.1007/s12029-018-0164-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
178 Schedel J, Pech O. Gastroösophagealer Reflux. CME 2018;15:9-20. [DOI: 10.1007/s11298-018-6510-y] [Reference Citation Analysis]
179 Shah AK, Hartel G, Brown I, Winterford C, Na R, Cao KL, Spicer BA, Dunstone MA, Phillips WA, Lord RV, Barbour AP, Watson DI, Joshi V, Whiteman DC, Hill MM. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus. Mol Cell Proteomics 2018;17:2324-34. [PMID: 30097534 DOI: 10.1074/mcp.RA118.000734] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
180 Hamade N, Vennelaganti S, Parasa S, Vennalaganti P, Gaddam S, Spaander MCW, van Olphen SH, Thota PN, Kennedy KF, Bruno MJ, Vargo JJ, Mathur S, Cash BD, Sampliner R, Gupta N, Falk GW, Bansal A, Young PE, Lieberman DA, Sharma P. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol 2019;17:864-8. [PMID: 30012433 DOI: 10.1016/j.cgh.2018.07.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
181 Wright NA. Is Barrett's-Associated Esophageal Adenocarcinoma a Clonal Disease? Dig Dis Sci 2018;63:2022-7. [PMID: 29951796 DOI: 10.1007/s10620-018-5164-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Konda VJA, Souza RF. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice. Dig Dis Sci. 2018;63:2070-2080. [PMID: 29713984 DOI: 10.1007/s10620-018-5088-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
183 Kuipers EJ, Spaander MC. Natural History of Barrett's Esophagus. Dig Dis Sci 2018;63:1997-2004. [PMID: 29905908 DOI: 10.1007/s10620-018-5161-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
184 Rogerson C, Britton E, Withey S, Hanley N, Ang YS, Sharrocks AD. Identification of a primitive intestinal transcription factor network shared between oesophageal adenocarcinoma and its pre-cancerous precursor state.. [DOI: 10.1101/373068] [Reference Citation Analysis]
185 Suhara H, Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Nakamura M, Miyahara R, Ishigami M, Hashimoto S, Goto H. Transabdominal ultrasound elastography of the esophagogastric junction predicts reflux esophagitis. J Med Ultrason (2001) 2019;46:99-104. [PMID: 30043241 DOI: 10.1007/s10396-018-0890-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
186 Schlottmann F, Molena D, Patti MG. Gastroesophageal reflux and Barrett’s esophagus: a pathway to esophageal adenocarcinoma. Updates Surg 2018;70:339-42. [DOI: 10.1007/s13304-018-0564-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
187 Choi WT, Tsai JH, Rabinovitch PS, Small T, Huang D, Mattis AN, Kakar S. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue. Gut 2018;67:1229-38. [PMID: 28642331 DOI: 10.1136/gutjnl-2017-313815] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
188 Han S, Wani S. Quality Indicators in Barrett's Esophagus: Time to Change the Status Quo. Clin Endosc 2018;51:344-51. [PMID: 30078308 DOI: 10.5946/ce.2018.099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
189 Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 2018;155:156-67. [PMID: 29608884 DOI: 10.1053/j.gastro.2018.03.047] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 20.5] [Reference Citation Analysis]
190 Krishnamoorthi R, Singh S, Ragunathan K, Visrodia K, Wang KK, Katzka DA, Iyer PG. Factors Associated With Progression of Barrett’s Esophagus: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:1046-1055.e8. [DOI: 10.1016/j.cgh.2017.11.044] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
191 Nieto T, Tomlinson CL, Dretzke J, Bayliss S, Price MJ, Dilworth M, Beggs AD, Tucker O. A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma. BMJ Open 2018;8:e020427. [PMID: 29961009 DOI: 10.1136/bmjopen-2017-020427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
192 Bresalier RS. Chemoprevention of Barrett’s Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci 2018;63:2155-62. [DOI: 10.1007/s10620-018-5149-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
193 Klavan H, Russell MB, Macklin J, Lee E, Aslanian HR, Muniraj T. Barrett's esophagus: A comprehensive review for the internist. Dis Mon 2018;64:471-87. [PMID: 29880269 DOI: 10.1016/j.disamonth.2018.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology 2018;95:81-90. [PMID: 29843157 DOI: 10.1159/000488489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Bellizzi AM, Hafezi‐bakhtiari S, Westerhoff M, Marginean EC, Riddell RH. Gastrointestinal pathologists’ perspective on managing risk in the distal esophagus: convergence on a pragmatic approach. Ann N Y Acad Sci 2018;1434:35-45. [DOI: 10.1111/nyas.13680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
196 Alcolea MP. Oesophageal Stem Cells and Cancer. Adv Exp Med Biol 2017;1041:187-206. [PMID: 29204834 DOI: 10.1007/978-3-319-69194-7_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
197 Shaheen NJ, Fennerty MB, Bergman JJ. Less Is More: A Minimalist Approach to Endoscopy. Gastroenterology 2018;154:1993-2003. [PMID: 29454789 DOI: 10.1053/j.gastro.2017.12.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
198 Waterhouse DJ, Fitzpatrick CRM, di Pietro M, Bohndiek SE. Emerging optical methods for endoscopic surveillance of Barrett's oesophagus. The Lancet Gastroenterology & Hepatology 2018;3:349-62. [DOI: 10.1016/s2468-1253(18)30030-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
199 Beg S, Mensa M, Fullard M, Finerty E, Richman P, Leahy A. Impact of advanced endoscopic imaging on Barrett’s esophagus in daily clinical practice. Gastrointestinal Endoscopy 2018;87:1189-94. [DOI: 10.1016/j.gie.2017.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
200 Braden B, Jones-Morris E. How to get the most out of costly Barrett's oesophagus surveillance. Dig Liver Dis 2018;50:871-7. [PMID: 29730158 DOI: 10.1016/j.dld.2018.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
201 Thrift AP. Barrett’s Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? Dig Dis Sci 2018;63:1988-96. [DOI: 10.1007/s10620-018-5068-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
202 Zakko L, Lutzke L, Wang KK. Screening and Preventive Strategies in Esophagogastric Cancer. Surg Oncol Clin N Am 2017;26:163-78. [PMID: 28279462 DOI: 10.1016/j.soc.2016.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
203 Kumar S, Iyer PG. Endoscopic eradication therapy for Barrett’s esophagus: Adverse outcomes, patient values, and cost-effectiveness. Techniques in Gastrointestinal Endoscopy 2018;20:75-81. [DOI: 10.1016/j.tgie.2018.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Yang D, Draganov PV. Endoscopic submucosal dissection compared to endoscopic mucosal resection for early Barrett esophagus neoplasia. Techniques in Gastrointestinal Endoscopy 2018;20:82-90. [DOI: 10.1016/j.tgie.2018.02.001] [Reference Citation Analysis]
205 Parasa S, Vennalaganti S, Gaddam S, Vennalaganti P, Young P, Gupta N, Thota P, Cash B, Mathur S, Sampliner R, Moawad F, Lieberman D, Bansal A, Kennedy KF, Vargo J, Falk G, Spaander M, Bruno M, Sharma P. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. Gastroenterology 2018;154:1282-1289.e2. [PMID: 29273452 DOI: 10.1053/j.gastro.2017.12.009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 19.3] [Reference Citation Analysis]
206 Offman J, Pesola F, Sasieni P. Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037. Br J Cancer 2018;118:1391-8. [PMID: 29563637 DOI: 10.1038/s41416-018-0047-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
207 Dunbar KB, Souza RF. Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk. Gastrointest Endosc Clin N Am 2017;27:447-59. [PMID: 28577766 DOI: 10.1016/j.giec.2017.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
208 Shah AK, Hartel G, Brown I, Winterford C, Na R, Lê Cao K, Spicer BA, Dunstone M, Phillips WA, Lord RV, Barbour AP, Watson DI, Joshi V, Whiteman DC, Hill MM. Serum glycoprotein biomarker validation for esophageal adenocarcinoma and application to Barrett’s surveillance.. [DOI: 10.1101/281220] [Reference Citation Analysis]
209 Kinsinger S. Elevated cancer risk perceptions among patients with Barrett's esophagus: do psychological factors play a role? Diseases of the Esophagus 2018;31. [DOI: 10.1093/dote/doy019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
210 Nam SY. Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver 2017;11:323-34. [PMID: 27890867 DOI: 10.5009/gnl15557] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 11.5] [Reference Citation Analysis]
211 Cook MB, Coburn SB, Lam JR, Taylor PR, Schneider JL, Corley DA. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort. Gut 2018;67:418-529. [PMID: 28053055 DOI: 10.1136/gutjnl-2016-312223] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
212 Masuda A, Fujita T, Murakami M, Yamazaki Y, Kobayashi M, Terao S, Sanuki T, Okada A, Adachi M, Shiomi H, Arisaka Y, Kutsumi H, Umegaki E, Azuma T. Influence of hiatal hernia and male sex on the relationship between alcohol intake and occurrence of Barrett's esophagus. PLoS One 2018;13:e0192951. [PMID: 29447244 DOI: 10.1371/journal.pone.0192951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
213 Yang D, Draganov PV. Expanding Role of Third Space Endoscopy in the Management of Esophageal Diseases. Curr Treat Options Gastroenterol 2018;16:41-57. [PMID: 29435819 DOI: 10.1007/s11938-018-0169-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
214 Tavakkoli A, Appelman HD, Beer DG, Madiyal C, Khodadost M, Nofz K, Metko V, Elta G, Wang T, Rubenstein JH. Use of Appropriate Surveillance for Patients With Nondysplastic Barrett's Esophagus. Clin Gastroenterol Hepatol 2018; 16: 862-869. e3. [PMID: 29432922 DOI: 10.1016/j.cgh.2018.01.052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
215 Schlottmann F, Patti MG, Shaheen NJ. From Heartburn to Barrett's Esophagus, and Beyond. World J Surg 2017;41:1698-704. [PMID: 28258457 DOI: 10.1007/s00268-017-3957-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
216 Tan WK, Rattan A, O'Donovan M, Nuckcheddy T, Alias B, Sujendran V, di Pietro M. Comparative outcomes of radiofrequency ablation for Barrett's oesophagus with different baseline histology. United European Gastroenterol J 2018;6:662-8. [PMID: 30083327 DOI: 10.1177/2050640617752183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
217 Itskoviz D, Levi Z, Boltin D, Vilkin A, Snir Y, Gingold-belfer R, Niv Y, Dotan I, Dickman R. Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up. Dig Dis Sci 2018;63:1513-7. [DOI: 10.1007/s10620-018-4910-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
218 Chattopadhyay TK. Advances in Gastrointestinal Surgery. GI Surgery Annual 2018. [DOI: 10.1007/978-981-13-0161-2_8] [Reference Citation Analysis]
219 Schlottmann F, Patti MG. Esophageal Adenocarcinoma: Pathogenesis and Epidemiology. Esophageal Cancer 2018. [DOI: 10.1007/978-3-319-91830-3_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
220 Qumseya BJ, Wallace M. Diagnostic Meta-Analysis: Case Study in Gastroenterology. Diagnostic Meta-Analysis 2018. [DOI: 10.1007/978-3-319-78966-8_17] [Reference Citation Analysis]
221 Khan T, Sharma P. Endoscopic Management of Barrett’s Esophagus. Clinical Gastroenterology 2018. [DOI: 10.1007/978-3-319-62993-3_6] [Reference Citation Analysis]
222 Valdovinos-andraca F, Bernal-méndez A, Barreto-zúñiga R, Briseño-garcía D, Martínez-lozano J, Romano-munive A, Elizondo-rivera J, Téllez-ávila F. Barrett's esophagus: Ten years of experience at a tertiary care hospital center in Mexico. Revista de Gastroenterología de México (English Edition) 2018;83:25-30. [DOI: 10.1016/j.rgmxen.2017.08.008] [Reference Citation Analysis]
223 Upchurch E, Griffiths S, Lloyd GR, Isabelle M, Kendall C, Barr H. Developments in optical imaging for gastrointestinal surgery. Future Oncol 2017;13:2363-82. [PMID: 29121775 DOI: 10.2217/fon-2017-0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
224 Rosmolen WD, Nieuwkerk PT, Pouw RE, van Berge Henegouwen MI, Bergman JJ, Sprangers MA. Quality of life and fear of cancer recurrence after endoscopic treatment for early Barrett's neoplasia: a prospective study. Dis Esophagus 2017;30:1-9. [PMID: 27766707 DOI: 10.1111/dote.12512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
225 Janmaat VT, van Olphen SH, Biermann KE, Looijenga LHJ, Bruno MB, Spaander MCW. Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis. PLoS One 2017;12:e0186305. [PMID: 29059206 DOI: 10.1371/journal.pone.0186305] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
226 Fauth L, Boettler T, Werner M. Präkanzerosen von Ösophagus, Magen und Kolon. Onkologe 2017;23:861-870. [DOI: 10.1007/s00761-017-0245-3] [Reference Citation Analysis]
227 Britton J, Keld R, Prasad N, Hamdy S, McLaughlin J, Ang Y. Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life. Lancet Gastroenterol Hepatol 2018;3:57-65. [PMID: 28970029 DOI: 10.1016/S2468-1253(17)30213-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
228 DE Carli DM, Araujo AF, Fagundes RB. LOW PREVALENCE OF BARRETT'S ESOPHAGUS IN A RISK AREA FOR ESOPHAGEAL CANCER IN SOUTH OF BRAZIL. Arq Gastroenterol 2017;54:305-7. [PMID: 28954045 DOI: 10.1590/S0004-2803.201700000-45] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
229 Stier MW, Lodhia N, Jacobs J, Nozicka D, Kavitt R, Siddiqui U, Waxman I, Konda VJ. Perceptions of risk and therapy among patients with Barrett's esophagus: a patient survey study. Diseases of the Esophagus 2017;31. [DOI: 10.1093/dote/dox109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
230 Matsuhashi N, Sakai E, Ohata K, Ishimura N, Fujisaki J, Shimizu T, Iijima K, Koike T, Endo T, Kikuchi T, Inayoshi T, Amano Y, Furuta T, Haruma K, Kinoshita Y. Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan. J Gastroenterol Hepatol 2017;32:409-14. [PMID: 27416773 DOI: 10.1111/jgh.13491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
231 Kojima K, Yamashita K, Ushiku H, Katoh H, Ishii S, Tanaka T, Yokoi K, Suzuki M, Ooizumi Y, Igarashi K, Hosoda K, Moriya H, Mieno H, Katada N, Tanabe S, Watanabe M. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. Dis Esophagus 2017;30:1-9. [PMID: 28184414 DOI: 10.1093/dote/dow001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
232 Wani S, Gaddam S. Editorial: Best Practices in Surveillance of Barrett's Esophagus. Am J Gastroenterol 2017;112:1056-60. [PMID: 28725066 DOI: 10.1038/ajg.2017.117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
233 Katz-Summercorn A, Anand S, Ingledew S, Huang Y, Roberts T, Galeano-Dalmau N, O'Donovan M, Liu H, Fitzgerald RC. Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus. J Pathol Clin Res 2017;3:258-67. [PMID: 29085666 DOI: 10.1002/cjp2.80] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
234 Adachi K, Mishiro T, Tanaka S, Kinoshita Y. Circumferential Locations of Different Shapes of Short-segment Barrett's Esophagus. Intern Med 2017;56:1937-42. [PMID: 28768960 DOI: 10.2169/internalmedicine.56.8260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
235 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 390] [Cited by in F6Publishing: 438] [Article Influence: 78.0] [Reference Citation Analysis]
236 Beane J, Campbell JD, Lel J, Vick J, Spira A. Genomic approaches to accelerate cancer interception. Lancet Oncol 2017;18:e494-502. [PMID: 28759388 DOI: 10.1016/S1470-2045(17)30373-X] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
237 Soucy G, Onstad L, Vaughan TL, Odze RD. Histologic Features Associated With Columnar-lined Esophagus in Distal Esophageal and Gastroesophageal Junction (GEJ) Biopsies From GERD Patients: A Community-based Population Study. Am J Surg Pathol 2016;40:827-35. [PMID: 26927889 DOI: 10.1097/PAS.0000000000000623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
238 Ten Kate FJC, van Olphen SH, Bruno MJ, Wijnhoven BPL, van Lanschot JJB, Looijenga LHJ, Fitzgerald RC, Biermann K. Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. Br J Surg 2017;104:1327-37. [PMID: 28692180 DOI: 10.1002/bjs.10553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
239 Quénéhervé L, The ESGE Guidelines committee, Barret M, Coron E. Recommandations européennes sur la prise en charge endoscopique de l’endobrachyœsophage. Acta Endosc 2017;47:174-179. [DOI: 10.1007/s10190-017-0600-7] [Reference Citation Analysis]
240 Valdovinos-Andraca F, Bernal-Méndez AR, Barreto-Zúñiga R, Briseño-García D, Martínez-Lozano JA, Romano-Munive AF, Elizondo-Rivera J, Téllez-Ávila FI. Barrett's esophagus: Ten years of experience at a tertiary care hospital center in Mexico. Rev Gastroenterol Mex (Engl Ed) 2018;83:25-30. [PMID: 28551084 DOI: 10.1016/j.rgmx.2017.03.007] [Reference Citation Analysis]
241 Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, Katelaris P, Tutuian RI, Castell DO. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017;77:547-61. [PMID: 28233274 DOI: 10.1007/s40265-017-0712-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 9.2] [Reference Citation Analysis]
242 Alkaddour A, Palacio C, Vega KJ. Risk of histologic Barrett's esophagus between African Americans and non-Hispanic whites: A meta-analysis. United European Gastroenterol J 2018;6:22-8. [PMID: 29435310 DOI: 10.1177/2050640617707862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
243 Srivastava A, Appelman H, Goldsmith JD, Davison JM, Hart J, Krasinskas AM. The Use of Ancillary Stains in the Diagnosis of Barrett Esophagus and Barrett Esophagus–associated Dysplasia: Recommendations From the Rodger C. Haggitt Gastrointestinal Pathology Society. American Journal of Surgical Pathology 2017;41:e8-e21. [DOI: 10.1097/pas.0000000000000819] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
244 Qumseya BJ, Wani S, Gendy S, Harnke B, Bergman JJ, Wolfsen H. Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017;112:849-865. [PMID: 28374819 DOI: 10.1038/ajg.2017.70] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
245 Abbosh C, Venkatesan S, Janes SM, Fitzgerald RC, Swanton C. Evolutionary dynamics in pre-invasive neoplasia. Curr Opin Syst Biol 2017;2:1-8. [PMID: 30603736 DOI: 10.1016/j.coisb.2017.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
246 Holmberg D, Ness-jensen E, Mattsson F, El-serag HB, Lagergren J. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. European Journal of Cancer 2017;75:41-6. [DOI: 10.1016/j.ejca.2016.12.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
247 Openshaw MR, Richards CJ, Guttery DS, Shaw JA, Thomas AL. The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Review of Molecular Diagnostics 2017;17:459-70. [DOI: 10.1080/14737159.2017.1308824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
248 Schlottmann F, Patti MG. Current Concepts in Treatment of Barrett's Esophagus With and Without Dysplasia. J Gastrointest Surg 2017;21:1354-60. [PMID: 28353175 DOI: 10.1007/s11605-017-3371-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
249 Coron E, Quénéhervé L. Dysplasie et endobrachyœsophage : les dernières recommandations européennes. Acta Endosc 2017;47:159-161. [DOI: 10.1007/s10190-017-0590-5] [Reference Citation Analysis]
250 Nguyen T, Thrift AP, Yu X, Duan Z, El-Serag HB. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol 2017;112:1049-55. [PMID: 28244499 DOI: 10.1038/ajg.2017.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
251 van Olphen SH, Ten Kate FJC, Doukas M, Kastelein F, Steyerberg EW, Stoop HA, Spaander MC, Looijenga LHJ, Bruno MJ, Biermann K; ProBar-Study Group. Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance: A multicenter case-control study. Medicine (Baltimore) 2016;95:e5402. [PMID: 27893678 DOI: 10.1097/MD.0000000000005402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
252 Lipman G, Haidry RJ. Endoscopic management of Barrett's and early oesophageal neoplasia. Frontline Gastroenterol 2017;8:138-42. [PMID: 28839898 DOI: 10.1136/flgastro-2016-100763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
253 Erichsen R, Horvath-Puho E, Lund JL, Dellon ES, Shaheen NJ, Pedersen L, Davey Smith G, Sørensen HT. Mortality and cardiovascular diseases risk in patients with Barrett's oesophagus: a population-based nationwide cohort study. Aliment Pharmacol Ther 2017;45:973-82. [PMID: 28139003 DOI: 10.1111/apt.13962] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
254 Lutz L, Werner M. [Barrett's esophagus and carcinoma: Recommendations of the S2k guideline 2014 and the S3 guideline 2015]. Pathologe 2016;37:193-8; quiz 199-200. [PMID: 26979429 DOI: 10.1007/s00292-016-0150-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
255 Faccio L, Zaninotto G. Surveillance in Barrett’s Esophagus and Dysplasia. Adenocarcinoma of the Esophagogastric Junction 2017. [DOI: 10.1007/978-3-319-28776-8_3] [Reference Citation Analysis]
256 Gatenby P, Bhattacharjee S, Wall C, Caygill C, Watson A. Risk stratification for malignant progression in Barrett’s esophagus: Gender, age, duration and year of surveillance. World J Gastroenterol 2016; 22(48): 10592-10600 [PMID: 28082811 DOI: 10.3748/wjg.v22.i48.10592] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
257 Evans RPT, Mourad MM, Fisher SG, Bramhall SR. Evolving management of metaplasia and dysplasia in Barrett's epithelium. World J Gastroenterol 2016; 22(47): 10316-10324 [PMID: 28058012 DOI: 10.3748/wjg.v22.i47.10316] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
258 Luigiano C, Iabichino G, Eusebi LH, Arena M, Consolo P, Morace C, Opocher E, Mangiavillano B. Outcomes of Radiofrequency Ablation for Dysplastic Barrett's Esophagus: A Comprehensive Review. Gastroenterol Res Pract. 2016;2016:4249510. [PMID: 28070182 DOI: 10.1155/2016/4249510] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
259 Nieto T, Tomlinson CL, Dretzke J, Bayliss S, Dilworth M, Beggs AD, Tucker O. Epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol. BMJ Open 2016;6:e013361. [PMID: 27927666 DOI: 10.1136/bmjopen-2016-013361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
260 Ahmed M. Barrett’s Oesophagus in 2016. EMJ Gastroenterol 2016. [DOI: 10.33590/emjgastroenterol/10311314] [Reference Citation Analysis]
261 Bureo Gonzalez A, Bergman JJ, Pouw RE. Endoscopic risk factors for neoplastic progression in patients with Barrett's oesophagus. United European Gastroenterol J 2016;4:657-62. [PMID: 27733907 DOI: 10.1177/2050640616635509] [Reference Citation Analysis]
262 Golger D, Probst A, Messmann H. Barrett's esophagus: lessons from recent clinical trials. Ann Gastroenterol 2016;29:417-23. [PMID: 27708506 DOI: 10.20524/aog.2016.0070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Whiteman DC, Kendall BJ. Barrett's oesophagus: epidemiology, diagnosis and clinical management. Medical Journal of Australia 2016;205:317-24. [DOI: 10.5694/mja16.00796] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
264 Gora MJ, Simmons LH, Quénéhervé L, Grant CN, Carruth RW, Lu W, Tiernan A, Dong J, Walker-Corkery B, Soomro A, Rosenberg M, Metlay JP, Tearney GJ. Tethered capsule endomicroscopy: from bench to bedside at a primary care practice.J Biomed Opt. 2016;21:104001. [PMID: 27689919 DOI: 10.1117/1.Jbo.21.10.104001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
265 Schoofs N, Bisschops R, Prenen H. Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. Ann Gastroenterol. 2017;30:1-6. [PMID: 28042232 DOI: 10.20524/aog.2016.0091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
266 Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G, Pandolfino JE, Sharma P, Ang TL, Hongo M, Wu J, Chen M, Choi MG, Law NM, Sheu BS, Zhang J, Ho KY, Sollano J, Rani AA, Kositchaiwat C, Bhatia S. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut 2016;65:1402-15. [PMID: 27261337 DOI: 10.1136/gutjnl-2016-311715] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 16.2] [Reference Citation Analysis]
267 Naini BV, Souza RF, Odze RD. Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol. 2016;40:e45-e66. [PMID: 26813745 DOI: 10.1097/pas.0000000000000598] [Cited by in Crossref: 77] [Cited by in F6Publishing: 109] [Article Influence: 12.8] [Reference Citation Analysis]
268 Suna N, Parlak E, Kuzu UB, Yildiz H, Koksal AS, Oztas E, Sirtas Z, Yuksel M, Aydinli O, Bilge Z, Taskiran I, Sasmaz N. The Prevalence of Barrett Esophagus Diagnosed in the Second Endoscopy: A Retrospective, Observational Study at a Tertiary Center. Medicine (Baltimore) 2016;95:e3313. [PMID: 27057907 DOI: 10.1097/MD.0000000000003313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
269 Martinez P, Timmer MR, Lau CT, Calpe S, Sancho-Serra Mdel C, Straub D, Baker AM, Meijer SL, Kate FJ, Mallant-Hent RC, Naber AH, van Oijen AH, Baak LC, Scholten P, Böhmer CJ, Fockens P, Bergman JJ, Maley CC, Graham TA, Krishnadath KK. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun 2016;7:12158. [PMID: 27538785 DOI: 10.1038/ncomms12158] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 10.3] [Reference Citation Analysis]
270 Panarelli NC, Yantiss RK. Do Ancillary Studies Aid Detection and Classification of Barrett Esophagus? American Journal of Surgical Pathology 2016;40:e83-93. [DOI: 10.1097/pas.0000000000000654] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
271 Gregson EM, Bornschein J, Fitzgerald RC. Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. Br J Cancer 2016;115:403-10. [PMID: 27441494 DOI: 10.1038/bjc.2016.219] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
272 Wennerström EC, Risques RA, Prunkard D, Giffen C, Corley DA, Murray LJ, Whiteman DC, Wu AH, Bernstein L, Ye W, Chow WH, Vaughan TL, Liao LM. Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma. Cancer Med 2016;5:2657-65. [PMID: 27384379 DOI: 10.1002/cam4.810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
273 Stier MW, Konda VJ, Hart J, Waxman I. Post-ablation surveillance in Barrett's esophagus: A review of the literature. World J Gastroenterol 2016; 22(17): 4297-4306 [PMID: 27158198 DOI: 10.3748/wjg.v22.i17.4297] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
274 Macías-García F, Domínguez-Muñoz JE. Update on management of Barrett's esophagus. World J Gastrointest Pharmacol Ther 2016; 7(2): 227-234 [PMID: 27158538 DOI: 10.4292/wjgpt.v7.i2.227] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
275 Graham D, Lipman G, Sehgal V, Lovat LB. Monitoring the premalignant potential of Barrett's oesophagus'. Frontline Gastroenterol 2016;7:316-22. [PMID: 27761232 DOI: 10.1136/flgastro-2016-100712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
276 Kastelein F, van Olphen SH, Steyerberg EW, Spaander MC, Bruno MJ; ProBar-Study Group. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression. Gut 2016;65:548-54. [PMID: 25903690 DOI: 10.1136/gutjnl-2014-308802] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
277 Ghaus S, Neumann H, Muhammad H, Tontini GE, Ishaq S. Diagnosis and Surveillance of Barrett’s Esophagus: Addressing the Transatlantic Divide. Dig Dis Sci 2016;61:2185-93. [DOI: 10.1007/s10620-016-4138-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
278 Thoguluva Chandrasekar V, Vennalaganti P, Sharma P. Management of Barrett's esophagus: Screening to newer treatments. Revista de Gastroenterología de México (English Edition) 2016;81:91-102. [DOI: 10.1016/j.rgmxen.2016.03.002] [Reference Citation Analysis]
279 Coman RM, Gotoda T, Forsmark CE, Draganov PV. Prospective evaluation of the clinical utility of endoscopic submucosal dissection (ESD) in patients with Barrett's esophagus: a Western center experience. Endosc Int Open 2016;4:E715-21. [PMID: 27556083 DOI: 10.1055/s-0042-101788] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
280 To H, Clemons NJ, Duong CP, Trainer AH, Phillips WA. The Genetics of Barrett’s Esophagus: A Familial and Population-Based Perspective. Dig Dis Sci 2016;61:1826-34. [DOI: 10.1007/s10620-016-4109-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
281 Thoguluva Chandrasekar V, Vennalaganti P, Sharma P. Management of Barrett's esophagus: From screening to newer treatments. Rev Gastroenterol Mex 2016;81:91-102. [PMID: 26964773 DOI: 10.1016/j.rgmx.2015.07.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
282 Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology 2016;150:599-607.e7; quiz e14-5. [PMID: 26619962 DOI: 10.1053/j.gastro.2015.11.040] [Cited by in Crossref: 109] [Cited by in F6Publishing: 115] [Article Influence: 18.2] [Reference Citation Analysis]
283 Thrift AP, Kendall BJ. Obesity in Relation to Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus. Curr Nutr Rep 2016;5:41-47. [DOI: 10.1007/s13668-016-0151-0] [Reference Citation Analysis]
284 Zeb MH, Baruah A, Kossak SK, Buttar NS. Chemoprevention in Barrett's Esophagus: Current Status. Gastroenterol Clin North Am 2015;44:391-413. [PMID: 26021201 DOI: 10.1016/j.gtc.2015.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
285 Gupta M, Iyer PG. Screening for Barrett's Esophagus. Gastroenterol Clin North Am 2015;44:265-83. [PMID: 26021194 DOI: 10.1016/j.gtc.2015.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
286 Theron BT, Padmanabhan H, Aladin H, Smith P, Campbell E, Nightingale P, Cooper BT, Trudgill NJ. The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort. United European Gastroenterol J 2016;4:754-61. [PMID: 28408992 DOI: 10.1177/2050640616632419] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
287 Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88-95. [PMID: 26851752 DOI: 10.1016/j.canep.2016.01.013] [Cited by in Crossref: 158] [Cited by in F6Publishing: 175] [Article Influence: 26.3] [Reference Citation Analysis]
288 Pohl H, Pech O, Arash H, Stolte M, Manner H, May A, Kraywinkel K, Sonnenberg A, Ell C. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 2016;65:196-201. [PMID: 26113177 DOI: 10.1136/gutjnl-2015-309220] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 12.2] [Reference Citation Analysis]
289 de Jonge PJ, Hvid-Jensen F. Barrett's oesophagus: size does matter. Gut 2016;65:189-90. [PMID: 26246246 DOI: 10.1136/gutjnl-2015-310091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
290 Whiteman DC, Appleyard M, Bahin FF, Bobryshev YV, Bourke MJ, Brown I, Chung A, Clouston A, Dickins E, Emery J. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2015;30:804-820. [PMID: 25612140 DOI: 10.1111/jgh.12913] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 12.8] [Reference Citation Analysis]
291 Murcia O, Gutiérrez A. Enfermedad por reflujo gastroesofágico. Medicine - Programa de Formación Médica Continuada Acreditado 2016;12:11-21. [DOI: 10.1016/j.med.2016.01.002] [Reference Citation Analysis]
292 Rau NB, Berzin TM. Screening and Surveillance of Barrett’s Esophagus. Barrett's Esophagus 2016. [DOI: 10.1016/b978-0-12-802511-6.00006-5] [Reference Citation Analysis]
293 Panarelli NC, Yantiss RK. The importance of biopsy sampling practices in the pathologic evaluation of gastrointestinal disorders. Curr Opin Gastroenterol 2016;32:374-81. [PMID: 28338484 DOI: 10.1097/MOG.0000000000000291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
294 Skaar DA, Jirtle RL, Hoyo C. Environmentally Induced Alterations in the Epigenome Affecting Obesity and Cancer in Minority Populations. Energy Balance and Cancer 2016. [DOI: 10.1007/978-3-319-41610-6_5] [Reference Citation Analysis]
295 Barrett Esophagus. Diagnostic Pathology: Gastrointestinal 2016. [DOI: 10.1016/b978-0-323-37673-0.50022-7] [Reference Citation Analysis]
296 Kim JG, Kim GH. Does the Risk of Esophageal Adenocarcinoma Increase as the Length of Barrett's Esophagus Becomes Long? Korean J Gastroenterol 2016;67:344. [DOI: 10.4166/kjg.2016.67.6.344] [Reference Citation Analysis]
297 Gharahkhani P, Tung J, Hinds D, Mishra A, Vaughan TL, Whiteman DC, MacGregor S; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON)., BEACON study investigators. Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus. Hum Mol Genet 2016;25:828-35. [PMID: 26704365 DOI: 10.1093/hmg/ddv512] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
298 Small AJ, Falk GW. Selection of patients for cancer prevention and eradication. Esophageal cancer and barrett's esophagus 2015. [DOI: 10.1002/9781118655153.ch22] [Reference Citation Analysis]
299 Sami SS, Ragunath K. Screening and surveillance. Esophageal cancer and barrett's esophagus 2015. [DOI: 10.1002/9781118655153.ch9] [Reference Citation Analysis]
300 Sharma N, Ho KY. Columnar lined Barrett's oesophagus. Br J Hosp Med (Lond) 2015;76:703-6. [PMID: 26646332 DOI: 10.12968/hmed.2015.76.12.703] [Reference Citation Analysis]
301 Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Wolfsen H, Chang KJ, Overholt BF, Pruitt RE, Ertan A, Komanduri S, Infantolino A, Rothstein RI, Shaheen NJ. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology 2015;149:1752-1761.e1. [PMID: 26327132 DOI: 10.1053/j.gastro.2015.08.048] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
302 Spechler SJ, Wang DH, Souza RF. Barrett Esophagus and Esophageal Adenocarcinoma. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch52] [Reference Citation Analysis]
303 Bus P, Kestens C, Ten Kate FJ, Peters W, Drenth JP, Roodhart JM, Siersema PD, van Baal JW. Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol. 2016;51:560-570. [PMID: 26585599 DOI: 10.1007/s00535-015-1133-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
304 Navab F, Nathanson BH, Desilets DJ. The impact of lifestyle on Barrett's Esophagus: A precursor to esophageal adenocarcinoma. Cancer Epidemiol 2015;39:885-91. [PMID: 26519660 DOI: 10.1016/j.canep.2015.10.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
305 Beg S, Wilson A, Ragunath K. The use of optical imaging techniques in the gastrointestinal tract. Frontline Gastroenterol 2016;7:207-15. [PMID: 27429735 DOI: 10.1136/flgastro-2015-100563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
306 Schölvinck DW, Goto O, Seldenrijk CA, Bisschops R, Horii J, Ochiai Y, Schoon EJ, Schenk BE, Uraoka T, van Oijen MGH, Bergman JJGHM, Yahagi N, Weusten BLAM. Detection of palisade vessels as a landmark for Barrett’s esophagus in a Western population. J Gastroenterol 2016;51:682-90. [DOI: 10.1007/s00535-015-1136-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
307 Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111:30-50; quiz 51. [PMID: 26526079 DOI: 10.1038/ajg.2015.322] [Cited by in Crossref: 971] [Cited by in F6Publishing: 1073] [Article Influence: 138.7] [Reference Citation Analysis]
308 Varghese S, Newton R, Ross-Innes CS, Lao-Sirieix P, Krishnadath KK, O'Donovan M, Novelli M, Wernisch L, Bergman J, Fitzgerald RC. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes. Gastroenterology 2015;149:1511-1518.e5. [PMID: 26248086 DOI: 10.1053/j.gastro.2015.07.053] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
309 Sturm MB, Wang TD. Emerging optical methods for surveillance of Barrett's oesophagus. Gut 2015;64:1816-23. [PMID: 25975605 DOI: 10.1136/gutjnl-2013-306706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
310 Pereira AD, Chaves P. Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence. United European Gastroenterol J 2016;4:343-52. [PMID: 27403300 DOI: 10.1177/2050640615612409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
311 Alkaddour A, Mcgaw C, Hritani R, Palacio C, Nakshabendi R, Munoz JC, Vega KJ. African American ethnicity is not associated with development of Barrett's oesophagus after erosive oesophagitis. Digestive and Liver Disease 2015;47:853-6. [DOI: 10.1016/j.dld.2015.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
312 di Pietro M, Bird-Lieberman EL, Liu X, Nuckcheddy-Grant T, Bertani H, O'Donovan M, Fitzgerald RC. Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrett's Esophagus. Am J Gastroenterol. 2015;110:1549-1558. [PMID: 26416188 DOI: 10.1038/ajg.2015.295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
313 Beales ILP, Dearman L, Vardi I, Loke Y. Reduced Risk of Barrett’s Esophagus in Statin Users: Case–Control Study and Meta-Analysis. Dig Dis Sci 2016;61:238-46. [DOI: 10.1007/s10620-015-3869-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
314 Coletta M, Sami SS, Nachiappan A, Fraquelli M, Casazza G, Ragunath K. Acetic acid chromoendoscopy for the diagnosis of early neoplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc. 2016;83:57-67.e1. [PMID: 26371851 DOI: 10.1016/j.gie.2015.07.023] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 9.1] [Reference Citation Analysis]
315 Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M. An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology 2015;149:577-85.e4; quiz e14-5. [PMID: 25935635 DOI: 10.1053/j.gastro.2015.04.045] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
316 Ma C, Pai RK. Predictive value of immunohistochemistry in pre-malignant lesions of the gastrointestinal tract. Seminars in Diagnostic Pathology 2015;32:334-43. [DOI: 10.1053/j.semdp.2015.02.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
317 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 217] [Cited by in F6Publishing: 240] [Article Influence: 31.0] [Reference Citation Analysis]
318 Ross-Innes CS, Becq J, Warren A, Cheetham RK, Northen H, O'Donovan M, Malhotra S, di Pietro M, Ivakhno S, He M, Weaver JMJ, Lynch AG, Kingsbury Z, Ross M, Humphray S, Bentley D, Fitzgerald RC. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet. 2015;47:1038-1046. [PMID: 26192915 DOI: 10.1038/ng.3357] [Cited by in Crossref: 209] [Cited by in F6Publishing: 216] [Article Influence: 29.9] [Reference Citation Analysis]
319 Li XM, Wang H, Zhu LL, Zhao RZ, Ji HL. Genes Regulating Epithelial Polarity Are Critical Suppressors of Esophageal Oncogenesis. J Cancer 2015;6:694-700. [PMID: 26185530 DOI: 10.7150/jca.11709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
320 Peter S, Mönkemüller K. Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia. Gastroenterology Clinics of North America 2015;44:337-53. [DOI: 10.1016/j.gtc.2015.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
321 Rubenstein JH. Surveillance in Barrett's Esophagus: Utility and Current Recommendations. Gastroenterol Clin North Am 2015;44:285-97. [PMID: 26021195 DOI: 10.1016/j.gtc.2015.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
322 Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol. 2015;110:662-682; quiz 683. [PMID: 25869390 DOI: 10.1038/ajg.2015.55] [Cited by in Crossref: 89] [Cited by in F6Publishing: 97] [Article Influence: 12.7] [Reference Citation Analysis]
323 Akiyama J, Alexandre L, Baruah A, Buttar N, Chandra R, Clark AB, Hart AR, Hawk E, Kandioler D, Kappel S, Krishnadath SK, Sharma A, Singh I, Straub D, Triadafilopoulos G, Umar A, Wolf B. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 2014;1325:108-26. [PMID: 25266020 DOI: 10.1111/nyas.12529] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
324 De Silva N, Fitzgerald R. Barrett's oesophagus and oesophageal adenocarcinoma. Medicine 2015;43:202-9. [DOI: 10.1016/j.mpmed.2015.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
325 Ortega Deballon P. Indications for Anti-Reflux Surgery in Barrett's Esophagus. Cirugía Española (English Edition) 2015;93:270-271. [DOI: 10.1016/j.cireng.2014.12.015] [Reference Citation Analysis]
326 Whitson MJ, Falk GW. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. Gastroenterol Clin North Am 2015;44:299-315. [PMID: 26021196 DOI: 10.1016/j.gtc.2015.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
327 Fisher OM, Levert-Mignon AJ, Lord SJ, Lee-Ng KK, Botelho NK, Falkenback D, Thomas ML, Bobryshev YV, Whiteman DC, Brown DA, Breit SN, Lord RV. MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma. Br J Cancer 2015;112:1384-91. [PMID: 25867265 DOI: 10.1038/bjc.2015.100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
328 Old O, Moayyedi P, Love S, Roberts C, Hapeshi J, Foy C, Stokes C, Briggs A, Jankowski J, Barr H; the BOSS Trial Team. Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen 2015;22:158-64. [DOI: 10.1177/0969141315575052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
329 Old OJ, Almond LM, Barr H. Barrett's oesophagus: how should we manage it? Frontline Gastroenterol 2015;6:108-16. [PMID: 28839797 DOI: 10.1136/flgastro-2014-100552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
330 Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:243-248. [PMID: 25666644 DOI: 10.1038/nrgastro.2015.24] [Cited by in Crossref: 102] [Cited by in F6Publishing: 108] [Article Influence: 14.6] [Reference Citation Analysis]
331 Blevins CH, Iyer PG. Endoscopic therapy for Barrett's oesophagus. Best Practice & Research Clinical Gastroenterology 2015;29:167-77. [DOI: 10.1016/j.bpg.2014.11.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
332 Ross-Innes CS, Debiram-Beecham I, O'Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, Sami SS, Kaye P, Novelli M, Disep B, Ostler R, Aigret B, North BV, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Sasieni PD, Fitzgerald RC; BEST2 Study Group. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med 2015;12:e1001780. [PMID: 25634542 DOI: 10.1371/journal.pmed.1001780] [Cited by in Crossref: 166] [Cited by in F6Publishing: 180] [Article Influence: 23.7] [Reference Citation Analysis]
333 Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open 2015;5:e006640. [PMID: 25633286 DOI: 10.1136/bmjopen-2014-006640] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
334 Ortega Deballon P. Indications for anti-reflux surgery in Barrett's esophagus. Cir Esp 2015;93:270-1. [PMID: 25616742 DOI: 10.1016/j.ciresp.2014.12.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
335 Falk GW. Barrett's oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol 2015;29:125-38. [PMID: 25743461 DOI: 10.1016/j.bpg.2015.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
336 Jankowski M, Wani S. Diagnostic and Management Implications of Basic Science Advances in Barrett’s Esophagus. Curr Treat Options Gastro 2015;13:16-29. [DOI: 10.1007/s11938-014-0040-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
337 Davelaar AL, Straub D, Buttar NS, Fockens P, Krishnadath KK. Active matrix metalloproteases are expressed early on and are high during the Barrett's esophagus malignancy sequence. Scand J Gastroenterol. 2015;50:321-332. [PMID: 25562781 DOI: 10.3109/00365521.2014.940379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
338 Madani A, Najmeh S, Aloraini A. Oesophageal Cancer. Pocket Manual of General Thoracic Surgery 2015. [DOI: 10.1007/978-3-319-17497-6_9] [Reference Citation Analysis]
339 Kanakadandi V, Sharma P. Barrett’s Esophagus. Gastrointestinal Endoscopy 2015. [DOI: 10.1007/978-1-4939-2032-7_1] [Reference Citation Analysis]
340 Golger D, Probst A, Messmann H. Evidenzbasiertes endoskopisches Management des Barrett-Ösophagus. Gastroenterologe 2015;10:7-16. [DOI: 10.1007/s11377-014-0936-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Jin Z, Zhang X, Fan X. Esophageal Cancer. Epigenetic Cancer Therapy 2015. [DOI: 10.1016/b978-0-12-800206-3.00016-1] [Reference Citation Analysis]
342 di Pietro M, Boerwinkel DF, Shariff MK, Liu X, Telakis E, Lao-Sirieix P, Walker E, Couch G, Mills L, Nuckcheddy-Grant T, Slininger S, O'Donovan M, Visser M, Meijer SL, Kaye PV, Wernisch L, Ragunath K, Bergman JJ, Fitzgerald RC. The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. Gut 2015;64:49-56. [PMID: 24721904 DOI: 10.1136/gutjnl-2013-305975] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
343 Sami SS, Dunagan KT, Johnson ML, Schleck CD, Shah ND, Zinsmeister AR, Wongkeesong LM, Wang KK, Katzka DA, Ragunath K, Iyer PG. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community. Am J Gastroenterol 2015;110:148-58. [PMID: 25488897 DOI: 10.1038/ajg.2014.362] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 8.9] [Reference Citation Analysis]
344 Kallam A, Alsop BR, Sharma P. Limitations of endoscopic ablation in Barrett's esophagus. Expert Rev Gastroenterol Hepatol 2015;9:487-96. [PMID: 25483982 DOI: 10.1586/17474124.2015.976554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
345 Zeki S, Fitzgerald RC. Targeting care in Barrett's oesophagus. Clin Med 2014;14:s78-83. [DOI: 10.7861/clinmedicine.14-6-s78] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
346 Naini BV, Chak A, Ali MA, Odze RD. Barrett's oesophagus diagnostic criteria: endoscopy and histology. Best Pract Res Clin Gastroenterol 2015;29:77-96. [PMID: 25743458 DOI: 10.1016/j.bpg.2014.11.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
347 Zeki S, Fitzgerald RC. The use of molecular markers in predicting dysplasia and guiding treatment. Best Pract Res Clin Gastroenterol 2015;29:113-24. [PMID: 25743460 DOI: 10.1016/j.bpg.2014.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
348 Lightdale CJ. Radiofrequency ablation for nondysplastic Barrett’s esophagus: certainly not for all. Gastrointest Endosc. 2014;80:873-876. [PMID: 25436399 DOI: 10.1016/j.gie.2014.05.331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
349 Ganz RA, Mitlyng B, Leon S. The case for ablating nondysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;80:866-872. [PMID: 25436398 DOI: 10.1016/j.gie.2014.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
350 Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M. The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Med Decis Making 2015;35:726-33. [PMID: 25277672 DOI: 10.1177/0272989X14551640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
351 Rubenstein JH. Improving the efficiency of Barrett's esophagus management: do biomarkers hit the mark? Gastrointest Endosc 2014;79:257-9. [PMID: 24433630 DOI: 10.1016/j.gie.2013.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
352 Gatenby P, Soon Y. Barrett’s oesophagus: Evidence from the current meta-analyses. World J Gastrointest Pathophysiol 2014; 5(3): 178-187 [PMID: 25133020 DOI: 10.4291/wjgp.v5.i3.178] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
353 Bandla S, Peters JH, Ruff D, Chen SM, Li CY, Song K, Thoms K, Litle VR, Watson T, Chapurin N, Lada M, Pennathur A, Luketich JD, Peterson D, Dulak A, Lin L, Bass A, Beer DG, Godfrey TE, Zhou Z. Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells. Ann Surg. 2014;260:72-80. [PMID: 24509200 DOI: 10.1097/sla.0000000000000424] [Cited by in Crossref: 33] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
354 Gatenby P, Caygill C, Wall C, Bhatacharjee S, Ramus J, Watson A, Winslet M. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus. World J Gastroenterol 2014; 20(28): 9611-9617 [PMID: 25071359 DOI: 10.3748/wjg.v20.i28.9611] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
355 Gordon LG, Mayne GC, Bright T, Whiteman DC, Watson DI. Response. Gastrointest Endosc 2014;80:191. [PMID: 24950651 DOI: 10.1016/j.gie.2014.02.020] [Reference Citation Analysis]
356 Ganz RA. Cost-effectiveness of Barrett's surveillance: a conceptual error. Gastrointest Endosc 2014;80:190. [PMID: 24950650 DOI: 10.1016/j.gie.2014.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
357 Sami SS, Ragunath K, Iyer PG. Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 2015;13:623-34. [PMID: 24887058 DOI: 10.1016/j.cgh.2014.03.036] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
358 Abrams JA, Appelman HD, Beer DG, Berry LD, Chak A, Falk GW, Fitzgerald RC, Ginsberg GG, Grady WM, Joshi BP, Lynch JP, Markowitz S, Richmond ES, Rustgi AK, Seibel EJ, Shaheen NJ, Shyr Y, Umar A, Wang KK, Wang TC, Wang TD, Yassin R. Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology 2014;146:1586-90. [PMID: 24768332 DOI: 10.1053/j.gastro.2014.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
359 Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG, Desai TK. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2014;79:897-909.e4. [DOI: 10.1016/j.gie.2014.01.009] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 17.6] [Reference Citation Analysis]
360 Dunbar KB, Spechler SJ. Controversies in Barrett esophagus. Mayo Clin Proc. 2014;89:973-984. [PMID: 24867396 DOI: 10.1016/j.mayocp.2014.01.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
361 Ramzan Z, Nassri AB, Huerta S. The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression. Expert Rev Mol Diagn 2014;14:575-91. [PMID: 24831686 DOI: 10.1586/14737159.2014.919856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
362 Pavlov K, Meijer C, van den Berg A, Peters FT, Kruyt FA, Kleibeuker JH. Embryological signaling pathways in Barrett's metaplasia development and malignant transformation; mechanisms and therapeutic opportunities. Crit Rev Oncol Hematol 2014;92:25-37. [PMID: 24935219 DOI: 10.1016/j.critrevonc.2014.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
363 Sharaiha RZ, Freedberg DE, Abrams JA, Wang YC. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett’s esophagus. Dig Dis Sci. 2014;59:1222-1230. [PMID: 24795040 DOI: 10.1007/s10620-014-3186-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
364 Bastard LC, Caserras XB. Seguimiento de las lesiones displásicas o premalignas del tubo digestivo. FMC - Formación Médica Continuada en Atención Primaria 2014;21:272-279. [DOI: 10.1016/s1134-2072(14)70761-3] [Reference Citation Analysis]
365 Masclee GM, Coloma PM, de Wilde M, Kuipers EJ, Sturkenboom MC. The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther. 2014;39:1321-1330. [PMID: 24738722 DOI: 10.1111/apt.12759] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
366 Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2014;23:997-1006. [PMID: 24692500 DOI: 10.1158/1055-9965.EPI-13-1233] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 6.5] [Reference Citation Analysis]
367 Zhang S, Zhang XQ, Ding XW, Yang RK, Huang SL, Kastelein F, Bruno M, Yu XJ, Zhou D, Zou XP. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer 2014;110:2378-88. [PMID: 24651385 DOI: 10.1038/bjc.2014.127] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
368 Coleman HG, Bhat SK, Murray LJ, McManus DT, O’Neill OM, Gavin AT, Johnston BT. Symptoms and endoscopic features at barrett’s esophagus diagnosis: implications for neoplastic progression risk. Am J Gastroenterol. 2014;109:527-534. [PMID: 24589668 DOI: 10.1038/ajg.2014.10] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
369 Kroep S, Lansdorp-vogelaar I, Rubenstein JH, Lemmens VEPP, van Heijningen EB, Aragonés N, van Ballegooijen M, Inadomi JM. Comparing Trends in Esophageal Adenocarcinoma Incidence and Lifestyle Factors Between the United States, Spain, and The Netherlands. American Journal of Gastroenterology 2014;109:336-43. [DOI: 10.1038/ajg.2013.420] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
370 Yates M, Cheong E, Luben R, Igali L, Fitzgerald R, Khaw KT, Hart A. Body mass index, smoking, and alcohol and risks of Barrett’s esophagus and esophageal adenocarcinoma: a UK prospective cohort study. Dig Dis Sci. 2014;59:1552-1559. [PMID: 24500448 DOI: 10.1007/s10620-013-3024-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
371 Fels Elliott DR, Fitzgerald RC. Molecular markers for Barrett's esophagus and its progression to cancer. Curr Opin Gastroenterol. 2013;29:437-445. [PMID: 23689523 DOI: 10.1097/mog.0b013e328362282f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
372 Butt J, Kandel G. Barrett esophagus: when to endoscope. Clin Endosc 2014;47:40-6. [PMID: 24570882 DOI: 10.5946/ce.2014.47.1.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
373 Armstrong D. Epidemiology of GERD, Barrett's Esophagus and Esophageal Cancer. GI Epidemiology 2014. [DOI: 10.1002/9781118727072.ch13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
374 Verbeek RE, van Oijen MG, ten Kate FJ, Vleggaar FP, van Baal JW, Siersema PD. Consistency of a high-grade dysplasia diagnosis in Barrett's oesophagus: a Dutch nationwide cohort study. Dig Liver Dis 2014;46:318-22. [PMID: 24388501 DOI: 10.1016/j.dld.2013.11.010] [Reference Citation Analysis]
375 de Jonge PJ, van Blankenstein M, Grady WM, Kuipers EJ. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 2014;63:191-202. [PMID: 24092861 DOI: 10.1136/gutjnl-2013-305490] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
376 Kestens C, van Hillegersberg R, Siersema P. Oesofaguscarcinoom. Ontwikkelingen in de oncologie 2014. [DOI: 10.1007/978-90-368-0436-3_24] [Reference Citation Analysis]
377 Kleinberg L, Kelly R, Yang S, Wang JS, Forastiere AA. Cancer of the Esophagus. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00074-6] [Reference Citation Analysis]
378 Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42. [PMID: 24165758 DOI: 10.1136/gutjnl-2013-305372] [Cited by in Crossref: 826] [Cited by in F6Publishing: 893] [Article Influence: 103.3] [Reference Citation Analysis]
379 Kestens C, van Hillegersberg R, Siersema P. Oesofaguscarcinoom. HUISARTS WETENSCHAP 2014;57:34-38. [DOI: 10.1007/s12445-014-0015-z] [Reference Citation Analysis]
380 Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) 2014;7:341-50. [PMID: 24380852 DOI: 10.1158/1940-6207.CAPR-13-0191-T] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
381 Watari J, Oshima T, Fukui H, Tomita T, Miwa H. Carcinogenesis of Barrett's esophagus: a review of the clinical literature. Clin J Gastroenterol 2013;6:399-414. [PMID: 26182128 DOI: 10.1007/s12328-013-0412-z] [Reference Citation Analysis]
382 Thrift AP, Kramer JR, Richardson PA, El-Serag HB. No significant effects of smoking or alcohol consumption on risk of Barrett’s esophagus. Dig Dis Sci. 2014;59:108-116. [PMID: 24114046 DOI: 10.1007/s10620-013-2892-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
383 di Pietro M, Fitzgerald RC. Research advances in esophageal diseases: bench to bedside. F1000Prime Rep. 2013;5:44. [PMID: 24167725 DOI: 10.12703/p5-44] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
384 Gordon LG, Mayne GC. Cost-effectiveness of Barrett’s oesophagus screening and surveillance. Best Pract Res Clin Gastroenterol. 2013;27:893-903. [PMID: 24182609 DOI: 10.1016/j.bpg.2013.08.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
385 Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Watson DI. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79:242-56.e6. [PMID: 24079411 DOI: 10.1016/j.gie.2013.07.046] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
386 Lenglinger J, See SF, Beller L, Cosentini EP, Asari R, Wrba F, Riegler M, Schoppmann SF. Review on novel concepts of columnar lined esophagus. Wien Klin Wochenschr 2013;125:577-90. [PMID: 24061694 DOI: 10.1007/s00508-013-0418-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
387 Sultan S, Falck-Ytter Y, Inadomi JM. The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol 2013;11:329-32. [PMID: 23517554 DOI: 10.1016/j.cgh.2013.02.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
388 Bus P, Siersema PD, Verbeek RE, van Baal JW. Upregulation of miRNA-143, -145, -192, and -194 in esophageal epithelial cells upon acidic bile salt stimulation. Dis Esophagus 2014;27:591-600. [PMID: 24006894 DOI: 10.1111/dote.12112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
389 Bornschein J, Fitzgerald RC. Barrett's oesophagus: diagnosis, surveillance and treatment. Br J Hosp Med (Lond) 2013;74:444-50. [PMID: 23958982 DOI: 10.12968/hmed.2013.74.8.444] [Reference Citation Analysis]
390 di Pietro M, Fitzgerald RC. Screening and risk stratification for Barrett’s esophagus: how to limit the clinical impact of the increasing incidence of esophageal adenocarcinoma. Gastroenterol Clin North Am. 2013;42:155-173. [PMID: 23452636 DOI: 10.1016/j.gtc.2012.11.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
391 Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, Bus P, van Baal JW. Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol 2014;49:1121-34. [PMID: 23955118 DOI: 10.1007/s00535-013-0862-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
392 Beales ILP, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther 2013; 4(3): 69-79 [PMID: 23919219 DOI: 10.4292/wjgpt.v4.i3.69] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
393 Lim YC, Fitzgerald RC. Diagnosis and treatment of Barrett's oesophagus. Br Med Bull 2013;107:117-32. [PMID: 23926313 DOI: 10.1093/bmb/ldt025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
394 Wanders LK, Dekker E, Pullens B, Bassett P, Travis SP, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:756-764. [PMID: 23920032 DOI: 10.1016/j.cgh.2013.07.024] [Cited by in Crossref: 125] [Cited by in F6Publishing: 131] [Article Influence: 13.9] [Reference Citation Analysis]
395 Kurian AA, Swanström LL. Radiofrequency ablation in the management of Barrett's esophagus: present role and future perspective. Expert Rev Med Devices 2013;10:509-17. [PMID: 23895078 DOI: 10.1586/17434440.2013.811863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
396 Corley DA. Can You Stop Surveillance After Radiofrequency Ablation of Barrett's Esophagus? A Glass Half Full. Gastroenterology 2013;145:39-42. [PMID: 23727498 DOI: 10.1053/j.gastro.2013.05.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
397 Estores D, Velanovich V. Barrett esophagus: epidemiology, pathogenesis, diagnosis, and management. Curr Probl Surg. 2013;50:192-226. [PMID: 23601575 DOI: 10.1067/j.cpsurg.2013.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
398 Max Almond L, Barr H. Management controversies in Barrett’s oesophagus. J Gastroenterol. 2013;Jun 5; Epub ahead of print. [PMID: 23736794 DOI: 10.1007/s00535-013-0816-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
399 Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. Gastroenterology 2013;144:1375-83, 1383.e1. [PMID: 23583429 DOI: 10.1053/j.gastro.2013.02.050] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
400 Kim GH. Columnar-lined Esophagus: Its Prevalence and Predictors in Patients With Gastroesophageal Reflux Disease (Am J Gastroenterol 2012;107:1655-1661). J Neurogastroenterol Motil 2013;19:261-3. [PMID: 23667760 DOI: 10.5056/jnm.2013.19.2.261] [Reference Citation Analysis]
401 Sostres C, Lacarta P, Lanas A. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?]. Gastroenterol Hepatol 2013;36:520-6. [PMID: 23453559 DOI: 10.1016/j.gastrohep.2012.11.010] [Reference Citation Analysis]
402 Terheggen G, Schumacher B. Barrett-Ablation. Gastroenterologe 2013;8:127-133. [DOI: 10.1007/s11377-012-0718-2] [Reference Citation Analysis]
403 Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:620-9. [PMID: 23357487 DOI: 10.1016/j.cgh.2012.12.036] [Cited by in Crossref: 122] [Cited by in F6Publishing: 135] [Article Influence: 13.6] [Reference Citation Analysis]
404 Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013;144:62-73.e6. [PMID: 23041329 DOI: 10.1053/j.gastro.2012.09.060] [Cited by in Crossref: 115] [Cited by in F6Publishing: 128] [Article Influence: 12.8] [Reference Citation Analysis]
405 Alvi MA, Liu X, O’Donovan M, Newton R, Wernisch L, Shannon NB, Shariff K, di Pietro M, Bergman JJ, Ragunath K. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res. 2013;19:878-888. [PMID: 23243219 DOI: 10.1158/1078-0432.ccr-12-2880] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
406 Mesteri I, Beller L, Fischer-see S, Schoppmann S, Lenglinger J, Wrba F, Riegler M, Zacherl J. Radiofrequency ablation of Barrett’s esophagus and early cancer within the background of the pathophysiology of the disease. Eur Surg 2012;44:366-82. [DOI: 10.1007/s10353-012-0183-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
407 Palma GDD. Management strategies of Barrett's esophagus. World J Gastroenterol 2012; 18(43): 6216-6225 [PMID: 23180941 DOI: 10.3748/wjg.v18.i43.6216] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
408 Boerwinkel DF, Di Pietro M, Liu X, Shariff MK, Lao-Sirieix P, Walker CE, Visser M, O' Donovan M, Kaye P, Bergman JJ, Fitzgerald RC. Endoscopic TriModal imaging and biomarkers for neoplasia conjoined: a feasibility study in Barrett's esophagus. Dis Esophagus 2014;27:435-43. [PMID: 23067399 DOI: 10.1111/j.1442-2050.2012.01428.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
409 Mesteri I, Lenglinger J, Beller L, Fischer-see S, Schoppmann SF, Wrba F, Riegler FM, Zacherl J. Assessment of columnar-lined esophagus in controls and patients with gastroesophageal reflux disease with and without proton-pump inhibitor therapy. Eur Surg 2012;44:304-13. [DOI: 10.1007/s10353-012-0159-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
410 Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol. 2012;107:1655-1661. [PMID: 23032983 DOI: 10.1038/ajg.2012.299] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
411 O'donovan M, Fitzgerald R. Dysplasia and early neoplasia in Barrett's oesophagus. Diagnostic Histopathology 2012;18:411-20. [DOI: 10.1016/j.mpdhp.2012.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
412 Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, Johnston BT, Arthur K, McManus DT, Novelli MR, O'Donovan M, Cardwell CR, Lovat LB, Murray LJ, Fitzgerald RC. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012;143:927-35.e3. [PMID: 22771507 DOI: 10.1053/j.gastro.2012.06.041] [Cited by in Crossref: 127] [Cited by in F6Publishing: 135] [Article Influence: 12.7] [Reference Citation Analysis]
413 Beales IL, Vardi I, Dearman L, Broughton T. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Dis Esophagus. 2012;Sep 18; Epub ahead of print. [PMID: 22989236 DOI: 10.1111/j.1442-2050.2012.01412.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
414 Schoppmann SF, Azari R, Riegler FM. Selected commentary to "Incidence of adenocarcinoma among patients with Barrett's esophagus". Eur Surg 2012;44:291-5. [DOI: 10.1007/s10353-012-0101-z] [Reference Citation Analysis]
415 Choi SE, Hur C. Screening and surveillance for Barrett's esophagus: current issues and future directions. Curr Opin Gastroenterol 2012;28:377-81. [PMID: 22508325 DOI: 10.1097/MOG.0b013e328353d58e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
416 Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012;143:567-75. [PMID: 22626608 DOI: 10.1053/j.gastro.2012.05.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 126] [Article Influence: 11.8] [Reference Citation Analysis]
417 Bergman JJGHM, Corley DA. Barrett's esophagus: who should receive ablation and how can we get the best results? Gastroenterology 2012;143:524-6. [PMID: 22841734 DOI: 10.1053/j.gastro.2012.07.094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
418 Nelsen EM, Hawes RH, Iyer PG. Diagnosis and management of Barrett's esophagus. Surg Clin North Am 2012;92:1135-54. [PMID: 23026274 DOI: 10.1016/j.suc.2012.07.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Nelsen EM, Hawes RH, Iyer PG. Diagnosis and management of Barrett’s esophagus. Surg Clin North Am. 2012;92:1135-1154. [PMID: 23026274 DOI: 10.1016/j.suc.2012.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
420 Frankel A, Nancarrow D, Wayte N, Barbour A. Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key? ANZ J Surg 2012;82:599-606. [PMID: 22856687 DOI: 10.1111/j.1445-2197.2012.06144.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
421 Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336-46. [PMID: 22537613 DOI: 10.1053/j.gastro.2012.04.032] [Cited by in Crossref: 277] [Cited by in F6Publishing: 303] [Article Influence: 27.7] [Reference Citation Analysis]
422 Lao-Sirieix P, Fitzgerald RC. Screening for oesophageal cancer. Nat Rev Clin Oncol. 2012;9:278-287. [PMID: 22430857 DOI: 10.1038/nrclinonc.2012.35] [Cited by in Crossref: 95] [Cited by in F6Publishing: 105] [Article Influence: 9.5] [Reference Citation Analysis]
423 Fitzgerald RC. Do transcription factors hold the key to understanding the development of Barrett's esophagus? Dig Dis Sci 2012;57:830-1. [PMID: 22367064 DOI: 10.1007/s10620-012-2068-9] [Reference Citation Analysis]
424 Wood NJ. Barrett esophagus: Need for ongoing surveillance called into question for patients with non-dysplastic Barrett esophagus. Nat Rev Gastroenterol Hepatol. 2011;8:657. [PMID: 22138905 DOI: 10.1038/nrgastro.2011.204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]